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Abstract 
Cancer is a generic term for a large group of diseases where cells of the body lose 
their normal mechanisms for growth so that they grow in an uncontrolled way. One of the 
most common treatments of cancer is chemotherapy that aims to kill abnormal proliferating 
cells; however normal cells and other organs of the patients are also adversely affected. In 
practice, it’s often difficult to maintain optimum chemotherapy doses that can maximise the 
abnormal cell killing as well as reducing side effects. The most chemotherapy drugs used in 
cancer treatment are toxic agents and usually have narrow therapeutic indices, dose levels in 
which these drugs significantly kill the cancerous cells are close to the levels which sometime 
cause harmful toxic side effects.  
To make the chemotherapeutic treatment effective, optimum drug scheduling is required to 
balance between the beneficial and toxic side effects of the cancer drugs. Conventional 
clinical methods very often fail to find drug doses that balance between these two due to their 
inherent conflicting nature. In this investigation, mathematical models for cancer 
chemotherapy are used to predict the number of tumour cells and control the tumour growth 
during treatment. A feedback control method is used so as to maintain certain level of drug 
concentrations at the tumour sites. Multi-objective Genetic Algorithm (MOGA) is then 
employed to find suitable solutions where drug resistances and drug concentrations are 
incorporated with cancer cell killing and toxic effects as design objectives. Several 
constraints and specific goal values were set for different design objectives in the 
optimisation process and a wide range of acceptable solutions were obtained trading off 
among different conflicting objectives.  
  Abstract 
 
v 
 
In order to develop a multi-objective optimal control model, this study used proportional, 
integral and derivative (PID) and I-PD (modified PID with Integrator used as series) 
controllers based on Martin’s growth model for optimum drug concentration to treat cancer. 
To the best of our knowledge, this is the first PID/I-PD based optimal chemotherapy control 
model used to investigate the cancer treatment. It has been observed that some solutions can 
reduce the cancer cells up to nearly 100% with much lower side effects and drug resistance 
during the whole period of treatment. The proposed strategy has been extended for more 
drugs and more design constraints and objectives.  
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CHAPTER 1 
Introduction 
1.1 Background 
Cancer is a generic term for a large group of diseases where cells of the body lose 
their normal mechanisms for growth so that they grow in an uncontrolled way (cancer 
research UK, 2011).  (T. Kirkwood, 2005). Cancer is a leading cause of death worldwide – 
nearly 12.7 million new cancer cases and 7.6 million cancer deaths (around 13% of all 
deaths) occurred in 2008. According to World Health Organization (WHO, 2011), the main 
types of cancer are: lung cancer, stomach cancer, liver cancer, colorectal cancer and breast 
cancer. The most commonly diagnosed cancers worldwide are breast, lung, colorectal and 
prostrate cancers, which constitute over half of all new cases diagnosed as shows Figure 1.1 
(A. Rachel, 2009). The most common causes of cancer death are lung, stomach and liver 
cancers (Cancer Research UK, 2011). More than 70% of all cancer deaths occurred in low- 
and middle-income countries. Deaths from cancer worldwide are projected to continue to rise 
to over 11 million in 2030 (WHO, 2011). 
Every year, more than 285,000 people are diagnosed with cancer in the United Kingdom, and 
the current estimate is that more than one in three people will develop a form of cancer at 
some point in their lifetime (Rachel, 2009). Around 309,500 people were diagnosed with 
cancer in the UK in 2008; this equates to around 504 cases for every 100,000 people (Cancer 
Research UK, 2011). 
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Cancer is an abnormal growth of cells caused by multiple changes in gene expression 
leading to dys-regulated balance of cell proliferation and cell death, and ultimately into a 
population of cells that can invade tissues and metastasize to distant sites. Cancer refers to a 
set of disease where normal cells of the body lose their mechanisms which are responsible for 
controlling their growth and motility. Cancer cells typically proliferate in an exponential 
fashion, the size of the cancerous mass is measured experimentally as a volume, though this 
mass is often referred to in terms of the number of cells 10
9 
(Martin and Teo, 1994).  
 
Fig. 1.1 The most commonly diagnosed cancers in the United Kingdom 2004 (Rachel, 2009). 
The main treatment of cancer includes surgery, radiotherapy, chemotherapy, hormone 
therapy, bisphosphonates, bone marrow and stem cell transplants, and biological, therapies. 
Chemotherapy is one of the essential and common treatments methods for cancer, these drugs 
treatment (i.e. treatment with cell killing (cytotoxic) drugs). Patients may have just one 
chemotherapy drug or a combination of different chemotherapy drugs. There are many 
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different drugs currently available and new ones are being developed all the time.  These 
drugs are often used as part of multimodality therapy that is along with surgery and/or 
radiotherapy to achieve and maintain remission. The process is likely to be long term where 
single agents or combination chemotherapy are given at intervals in pulsed doses or in cycles 
and are highly dependent upon the tumour type and characteristics. Monitoring of the patient 
takes place throughout the process, so that tumour response to therapy or incidences of 
tumour progression can be tracked and treatment aims adjusted accordingly. 
The treatment given for cancer is highly variable and dependent on a number of 
factors including the type, location and amount of disease and the health status of the patient. 
The treatments are designed to either directly kill/remove the cancer cells or to lead to their 
eventual death by depriving them of signals needed for cell division. Other treatments work 
by stimulating the body's own defences. There are many cancer drugs existing and over 50 
chemotherapy drugs that are commonly used (Robert, et al., 1998, Mahtani, 2010). Table 1.1 
includes some of the examples of chemotherapy drugs, how they administrated, their usage of 
the drug and their various side effects. Side effects may occur just after treatment (days or 
weeks) or they may occur later (months or years) after the chemotherapy has been given 
(Richard, et al., 1996, Robert, et al., 1998, Michael, 2001, Mahtani, 2010). 
 
 
 
 
  CHAPTER 1 
 
4 
 
Table: 1.1 Chemotherapy drugs used in cancer (M. Neal, 2005) 
Group Example Mode of action 
Alkylating agent Chlormethine, 
cyclophosphamite, 
chlorambucil, cisplatin 
and busulphan  
Act with the bases in DNA and 
prevent cell division by cross-
linking the two stands of double 
helix. 
Antimetabolite Methotrexate and 
fluorouracil 
Inhibits dihydrofolate reductase. 
Inhibits thymidylate synthetase. 
Antibiotic Doxorubin, 
dactinomycine and 
bleomucin 
Intercalate between base pairs 
block RNA production. 
Degrades DNA by formation free 
radicals. 
Vinca alkaloids Vincristine, vinblastine 
and paclitaxel 
Inhibit mitosis by binding to the 
micro-tubular proteins necessary 
for spindle formation. 
Monoclonal ant-bodies Trastuzumab and 
rituximab 
Act with antigen specifically 
expressed on cancer cells. 
The main aim of chemotherapy is to minimise/eliminate the number of cancer cells after a 
number of fixed treatment cycles with minimum toxic side effects. A cell is considered 
cancerous when it has lost its mechanism to divide normally. Traditionally one or more 
chemotherapy cancer drugs are infused to the body depends of the needs. The efficiency of 
the doses of the treatment is often measured as the interval of time from the start of therapy, 
until the end of treatment.  
Chemotherapy creates a damaging range of side-effects as shows Table 1:2, and so it 
is normally given in cycles of treatment which alternate with rest periods, to allow the body 
to recover. Several cycles of treatment are needed, as chemotherapy only attacks cells that are 
actively dividing. At any one time, some cancer cells will be dormant, and may not be killed 
until a later round of drug treatment. The number and duration of these rounds depends on 
many factors including the type of cancer, how advanced it is, and the general health of the 
patient being treated (i. e, patient suffering from other diseases). 
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Table: 1.2 Effect of cytotoxic drugs (L. John, et al., 1993) 
Drug Mechanism Specific adverse 
effects 
Indications 
Cyclophosphamide Alkylating agent Haematuria, cystitis Haematological malignancy, 
solid tumour 
Doxorubicin Antibiotic Alopecia, cardiac 
arrhythmia, local 
tissue necrosis 
Wide range of 
Haematological 
Cisplatin Interacts with 
DNA 
Neurotoxicity 
Nephrotoxicity 
Vomiting 
Wide range of solid tumours, 
including lung, ovarian and 
testicular carcinoma 
Bleomycin Antibiotic Pulmonory fibrosis, 
skin rashes 
Lymphomas, testicular 
tetratoma, squamous cell  
carcinoma 
Methotrexate Antimetabolite Mucositis Leukaemia 
The oldest documented in the world about the case of cancer disease was written in 
Egypt by ancient Egyptians, in 1500 b. c. The details about eight cases of the cancer disease 
occurring on the breast were recorded and treated by cauterization, a method to destroy tissue 
with a hot instrument called "the fire drill". (F. Lisa, 2009). There is evidence that the ancient 
Egyptians were able to tell the difference between malignant and benign tumours. According 
to inscriptions, surface tumours were surgically removed in a similar manner as they are 
removed today.  
Recently, so much information is available about the human body. Hippocrates 
believed that the body was composed of four fluids: blood, phlegm, yellow bile and black 
bile. He believed that an excess of black bile in any given site in the body caused cancer. This 
was the general thought of the cause of cancer for the next 1400 years.  In ancient Egypt, it 
was believed cancer was caused by the Gods (www.cancer.org, 2011, F. Lias, 2009).  
Today, the human body has been described each organ separately and in very small 
details. The scientists now dealing with small part of the organ (called cell), the scientists are 
very lucky now because of the information which they got about the cancer disease, so many 
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researchers in different areas are working together side by side to find the best treatment of 
this disease. Many mathematical models created and developed for the tumour cells 
proliferating and their behaviours, before and after the period of treatment. 
Researchers have designed optimal drug schedules of cancer chemotherapy and 
developed many mathematical models to predict tumour growth after the administration of 
chemotherapy. A number of models have been used to characterise the evolution and effects 
of treatment on cancer (Westman, et al., 2001; Liang, et al., 2006; Ochoa, et al., 2007) to 
reduce the side-effects. There are several reasons why a good mathematical model is very 
useful. For example, in animals the disease may take months to run its course, and in human, 
years also the clinical trials are costly and limited (R. Frank, 2011). It is often quicker and 
cheaper to formulate a mathematical model and simulate it on computer than perform a 
laboratory experiments or clinical trials (Martin and Teo, 1994). Martin (1992) proposed an 
optimal drug scheduling model and established numerical solution technique known as the 
control parameterisation and analytical gradients to construct a mathematical model with all 
constraints of cancer drug chemotherapy treatment.  
Considering the complexity of designing a schedule that achieves certain goals whilst 
moderating the cancer drug’s toxic side-effects, the idea of providing computer-based 
decision support system is appealing. The proposed Genetic algorithms (GAs) as a search 
tool in a decision support system for designing chemotherapy schedules. Using an underlying 
mathematical model that captures the essential qualitative features of a cancer tumour, the 
purpose is to use chemotherapy to control the system, and drive it into a desirable (minimal) 
tumour level after which the body could eliminate the remaining cancerous cells. This 
problem can be formulated as an optimisation problem and refers to a problem of finding a 
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control scheme for a given dynamic system, such that a certain optimality criterion is 
achieved.  
In general, most chemotherapy drugs used in cancer treatment are toxic agents and 
usually have narrow therapeutic indices; dose levels in which these drugs significantly kill 
the cancerous cells are close to those levels which sometime cause harmful toxic side effects. 
Therefore, effective drug scheduling requires suitable balancing between the beneficial and 
toxic side effects.  
Conventional clinical methods very often fail to find drug doses that balance between 
these two due to their inherent conflicting nature. The purpose is to design and implement a 
method of chemotherapy drug scheduling that can provide solutions trading-off between the 
cell killing and toxic side effects during the whole period of treatment.  The model designed 
to control the drug to be infused to the patient’s body using optimisation techniques to find 
suitable/acceptable drug concentration at tumour site and parameters of the controller. 
1.2 Uncertainty in Optimal Treatment Model 
The chemotherapy cancer drug treatment is very sensitive due to various uncertainty 
issues involve in the treatment process. Among these issues, the most important two are: (i) 
uncertainty due to the sensitivity of the patient and (ii) uncertainty associated with the drug 
administration process. This research focuses in chemotherapy cancer treatment through 
optimal drug administration in which risk could be stimulated due to optimisation through 
probability based Genetic Algorithm model. The Genetic Algorithm is used to tune the 
controller parameters to find the suitable value of each parameter for optimal solution. In this 
investigation, to avoid any uncertainty in the model, the optimisation process was run for 
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many generations in order to minimise all objectives simultaneously in an offline manner. 
Solutions not satisfying design constraints are penalised with very high values called penalty 
function. This penalty function reduces the probability of solutions yielding unacceptable 
values along any design objectives dominate the optimisation process, and on the contrary, 
favour acceptable solutions can be selected for reproduction that in turn may generate better 
solutions in subsequent generations. In optimisation process, non-dominated solutions called 
Pareto optimal set and corresponding decision variables are updated and preserved at the end 
of each generation. The parameters of the offline optimisation process are then applied to the 
proposed control model to test and validate the proposed scheme. Thus, the proposed scheme 
is considered to overcome the uncertainty factor for the treatment model. However, the 
uncertainty or risk associated with patient is beyond the scope of this research and is 
considered for future investigation. 
1.3 Motivation 
Cancer is a disease caused by normal cells, when start changing and growth in an 
uncontrolled way. The uncontrolled growth causes a lump called a tumour. There are over 
200 different types of cancer; many people diagnosed that have one of these particular type of 
cancer disease every year. The survival time of the cancer patients is between 5 and 10 years 
time period after diagnosed initial diagnosis (cancerhelp.cancerreasechuk, 2011). There is no 
cure or perfect drug or treatment has been invented yet for cancer, so it is important to 
undertake research in this field to save lives of many people.  There is a need to design, 
develop and implement the strategies of the cancer chemotherapy treatment in order to help 
the patients by balancing between the drug effectiveness and the side-effects. The idea is to 
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minimise the number of cancer cells of the patient, using a number of fixed of treatment 
cycles, and targeting minimum toxic side effects.    
An automatic system of drug scheduling infused to the patient body can be reliable 
and safer than a manual one (Ronda and Blegen, 2008). This can be achieved by different 
approaches of treatments like single drug or multi-drug to increase the quality and the 
effectiveness of the chemotherapy treatment by decreasing the chance of the cancer cells 
resistance to the drug and eliminating any toxic side-effects of the treatment. Furthermore, 
the models for cancer chemotherapy treatment can be used to predict tumour growth and 
control the disease during the course of treatment by minimising the number of cancer cells 
and maximising the survival time of the patient. Control systems theory has been extended 
into many fields, medicine is not an exception, although the progress is slow in some cases 
due to particular challenges encountered by the inherent of the nature complexity of 
biological system (Ronda and Blegen, 2008). After more than three decades of research in 
this filed, still there is little points have been considered in the actual clinical environment. 
The main motivation of this research is to give this area another push towards this goal.  
Current clinical practice involves manual regulation to infuse drugs into the patient’s 
body. Programmable pumps are also used to either deliver the drugs at a constant rate or a 
variable rate to achieve a desired concentration. Control of such pumps is based on averaged 
pharmacokinetic data and is essentially open loop, requiring regular intervention by the 
attending physician or nurse to adjust the drug flow rates. It is desirable to have an automated 
system that closes the loop on primary variables, but monitor secondary variables and helps 
the physician to perform diagnosis. This would allow the physician to spend more time 
monitoring the patient conditions that are not easily measured and assure that the physician is 
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always “in the loop”. The physician would use his/her expertise to diagnose the patient, 
specify set points or ranges of values for the states to be regulated, close the drugs best suited 
to obtain the objective, and mandate permissible infusion rates, this information would then 
be explicitly used by the controller to automate the regulation of physiological states. 
The close loop control system for the drug administration is the target in 
investigations as the drug is the main player in this work. Moreover, by applying optimal 
volumes of drug doses to the patients will meet the desired impact of cancer treatment. The 
main aim is to design mathematical models to control cancer chemotherapy treatment by 
scheduling the cancer drug during the whole period of treatment cycle. Therefore, the focus 
of this research will be in the area of drug scheduling to achieve the objectives by making the 
treatment more efficient in maximising the cancer cells killing and minimising the toxic side 
effect. 
1.4 Aims and Objectives 
The most important target of this investigation is to design and implement a model for 
optimal drug control scheme for cancer in order to meet the desired impact of cancer 
chemotherapy treatment. The development of optimal chemotherapy control model to 
minimise/eliminate the cancer cells after a number of fixed treatment cycles with minimum 
toxic side effects in order to improve the quality of life to the cancer patient. Moreover 
increases the effectiveness of greater cell kill by combining different type of cancer 
chemotherapy drug, decreases the chance of drug resistance by using drug combination and 
reduces any toxic side effects, also maximising the survival time of the patient life. 
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  The cancer tumour model should be designed based on the cancer cells functions in 
order to show the effects of drug on different cell populations, drug concentration and toxic 
side effects. The using of multi-objective optimisation approach could generate a wide range 
of solutions that trade-off between cell killing and toxic side effects and satisfy associated 
goals of chemotherapy treatment. Depending on the physiological state of the patient and 
state of the cancer, the oncologist can pick the right solution suitable for the patient.  
In order to achieve the aim, this study undertakes the following strategies to:  
 Make the treatment more effective by balancing between the beneficial and the side-
effect of the treatment. Understanding the system of the cancer cell (i. e, the function 
and life cycle) is required and a description of the effects of the chemotherapy 
treatment (i. e, maximising tumour cell killing, minimum toxicity and tolerable drug 
concentration) must be balanced to achieve the designing and implementing of the 
models.  
 Design, develop and implement mathematical and computational models for cancer 
chemotherapy to predict the number of tumour cells and control the tumour growth 
during treatment. Developing these models and demonstrating the interactions 
between tumour and normal cells can affect the outcome of the treatment and the 
ability for a tumour to recur, which requires an understanding of the system in 
absence of treatment and a description of the treatment effects 
 Develop controller to control the dosage of drug during the period of the treatment 
cycle to give the system more reliability by monitoring, and control the growth of 
tumour cells and the drug side-effect toxic.  
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 Optimise chemotherapy scheduling to increase the effectiveness of the cancer 
treatment chemotherapy and decrease the resistance of the treatment during the 
treatment cycle, in turn reduce the chance of the side-effect toxic.   
1.5 Organisation of the Thesis 
 Chapter 1 (Introduction) presents background and history about the cancer, motivation, 
the aims and objective of my work.  
 Chapter 2 (literature review) introduces the literature review about the cancer disease 
including cancer growth modelling, optimal chemotherapy for cancer treatment, cells 
phase specific and non phase specific, combination of chemotherapy regime and drug 
resistance. 
 Chapter 3 (Methodology) presents the proposed cancer treatment methodology, 
mathematical model for cancer drug scheduling, non phase specific, phase specific, four 
compartments, eight compartments, PID controller and  optimisation techniques Multi-
Objective Genetic algorithm (MOGA). 
 Chapter 4 (Experiments and result) provides an overview and the results which have been 
implemented about non phase specific treatment, phase specific cancer cell treatment, 
four compartments model and proposed control sachem for eight compartments model. 
 Chapter 5 (Comparative study) presents the comparisons of results produced by the 
systems implemented for non phase specific, phase specific with exist results, 
comparative between MOGA and Multi-Objective Particle swarm algorithm (MOPSO) 
phase specific model has been included as well, four compartment cancer cells model and 
eight compartment cancer cells model also covered in this Chapter. 
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 Finally, Chapter 6, includes the thesis conclusion, contributions and future direction of 
this research 
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CHAPTER 2  
 Literature Review 
2.1   Introduction 
Many mathematical models have been developed to describe the growth and control of   
tumours (Martin and Teo, 1994, Westman et al., 2002, Dua, 2008). These models considered 
the effect of the drug as well as the reactions of the cancer cells to chemotherapy treatment. 
These mathematical models are basically ordinary differential equations that describe the 
growth of the cancer cells along with the effects of chemotherapy treatment.  
Mathematical models of cancer chemotherapy can demonstrate the interactions between 
tumour and normal cells, outcome of the cancer drug chemotherapy treatment and the ability 
for a tumour to recur (Panetta, 1996). The tumour cell population may be calculated from 
tumour volume measurements, since there is an approximately linear relationship between 
tumour volume and cell number (Stephens and Peacock, 1977). 
A mathematical model can be used to model the growth of tumour cancer cells, 
provided that an initial tumour cell population is specified together with some general 
assumptions about the way in which the tumour grows. The purpose of using mathematical 
models of cancer chemotherapy is to predict and control the course of the disease when a 
given treatment is being used. 
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Also mathematical models are used to find the optimal cancer chemotherapy protocols 
which could minimise the number of the tumour cells to the minimum level with less side-
effect by different optimisation methods. There are some numerical solution techniques that 
have been established to construct a mathematical model with all constraints (Martin and 
Teo, 1994). 
The understanding of the system and a description of the effects of the treatment is 
required when designing and developing of the model which is desired to balance the benefits 
of the conflicts. The developing of the mathematical model in order to demonstrate the 
interactions between tumour and normal cells can affect the outcomes of the treatment and 
the ability for a tumour to recur. The main aspect of this review is to highlight the advantages 
which have been achieved, to avoid the weaknesses of the previous models identified and 
finally to propose new models to improve cancer treatment.  
The aim of this Chapter is to conduct a literature review on cancer growth model, 
optimal chemotherapy for cancer model, phase specific and non-phase specific treatment 
models, combination of chemotherapy regimen, and mechanism and implications of drug 
resistance, related to the objectives of this study. The main aim is to predict the cancer cells 
populations and the growth rate of the cancer cells in order to estimate the treatment cycles. 
Some of the treatment models consider the cancer cells as a one compartment meaning that 
the behaviours of all cancer cells are similar.  The balance between the benefits of the 
treatment in this case is to reduce the side-effects of the treatment. The proliferating cells at 
the tissue level are considered as active cancer cells and need to be treated by dividing them 
into two compartments (Proliferating and Quiescent cells) called cell phase specific model. 
The drug resistance has not been taken in account on the last two types of cancer 
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chemotherapy treatment models introduced by Martin and Liang (Martin and Teo, 1994, 
Liang et al, 2006).   The multi-drug regimens models are designed to avoid the weaknesses of 
the previous cancer treatment models relating to the resistance of the cancer cells to the 
cancer drug.  The cancer cells are divided into four and eight compartments and can be 
expended to more compartments based on the sensitivity of the cancer cell to drug.   
2.2 Cancer Growth model 
Cancer refers to a set of disease where normal cells of the body lose their mechanisms 
which are responsible for controlling their growth and motility. Cancer cells typically 
proliferate in an exponential fashion, the size of the cancerous mass is measured 
experimentally as a volume, though this mass is often referred to in terms of the number of 
cells 10
9 
(Martin and Teo, 1994). The cancer cells growth as known in groups called 
tumours.  A tumour is characterised by the number of cells or the size of tissue it contains, 
and the growth characteristics of individual normal cells within a tumour are influenced by 
the neighbouring cancer cells. The cell cycle is a sequence of phases that both normal and 
malignant cells undergo from their birth to death; consist of five stages as shown in Figure 
1.2 in Chapter 1 (Liang, et, el, 2008). The tumour cell population may be calculated from 
tumour volume measurements, since there is an approximately linear relationship between 
tumour volume and cell number (Martin and Teo, 1994). 
The tumour cell population may be calculated from tumour volume measurements, 
since there is an approximately linear relationship between tumour volume and cell number. 
A mathematical model used to predict and control the growth of tumour provide that an 
initial tumour cell population is specified together with some general assumptions about the 
way in which the tumour is growing which called a ordinary differential equation (ODE). The 
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mathematical models of cancer chemotherapy are to predict and control the course of the 
disease when a given treatment is being used. There are three growth models used to simulate 
and predict different type of tumour growth introduced by Martin, these include Gompertz, 
Logistic and exponential (Westman, et al., 2002). For all three models the initial tumour 
burden is      cells and the initial tumour population doubling time is 4 weeks as shows 
Figure 2.1 (Martin and Teo, 1994).  
Ń (t) = λE N                         exponential                  (1) 
Ń (t) = λL N (1-N/θ)            logistic                        (2) 
Ń (t) = λG  N ln (θ /N)        Gompertz                   (3) 
 
Fig. 2.1 Different models of calculating the cell populations 
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2.3 Optimal Chemotherapy for Cancer Treatment  
Many studies proposed algorithms to design an optimal chemotherapy drug protocol 
for the treatment of cancer (Costa, et al., 1992, Martin and Teo, 1994, Bojkov, et al., 1993, 
Liang, et al., 2006). The target was to optimise the number of the treatment cycles and the 
drug doses. A mathematical model is employed in the form of ordinary differential equations 
controlling cancer tumour growth on a cell population level.  
The most types of the cancer diseases are formulated for optimal control problems 
with a set of dynamic differential equations in the state space form (Neilan and Lenhart, 
2010). The objectives functions are considered to minimise the tumour size as well as 
treatment side-effects under a set of constraints using optimisation techniques. Also, the drug 
resistant effect is considered on some models in the optimal treatment schedule (Westman, et 
al., 2002). The optimal cancer chemotherapy protocols are chosen to minimise the number of 
the tumour cells with less side-effect by different optimisation methods. 
Alam and co-workers in (2010) developed a method of phase specific drug 
scheduling using a close-loop control method and multi-objective particle swarm 
optimisation algorithm (MOPSO) that can provide solutions for trading-off between the 
cell killing and toxic side effects. A close-loop control method, namely Integral-
Proportional-Derivative (I-PD) is designed to control the drug to be infused to the 
patient’s body and MOPSO is used to find suitable parameters of the controller. A 
phase specific cancer tumour model is used for this work to show the effects of drug on 
tumour.  
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An important target for cancer chemotherapy treatment is to maximise the cancer 
cells killing for a fixed treatment cycle. So, the drug scheduling of cancer chemotherapy 
treatment is essential for successful treatment. (Martin, 1992) proposed an optimal drug 
scheduling model and a numerical solution technique known as the control parameterisation 
and analytical gradients to construct a mathematical model with all constraints cells killing, 
side-effect and drug concentration of cancer drug chemotherapy treatment. Numerical 
solutions suggest that the best way of reducing the tumour burden after a fixed period of 
treatment is to keep the rate of decrease of the tumour size to a minimum initially, and then 
give high-intensity treatment towards the end of the treatment period. 
The results were improved by Bojkov, et al., (1993), who used an intuitive approach 
coupled with the direct search procedure proposed in Luus (1998). Based on approaches of 
random numbers and search region contraction, a method of direct search optimisation was 
applied to solve the problem (Luus, 1995).  
Carrasco and Banga (1998) proposed an adaptive stochastic algorithm to find the 
optimal control policy for cancer drug scheduling to maximise the killing of the tumour cells 
as measured at some particular time in the future. They suggested that drug concentration 
must be kept at the tolerable level throughout the treatment period and the cumulative toxicity 
effect of the drug must be kept below the ultimate tolerance level.  
Swan in (1998) introduced two basic theoretical models, which demonstrated cancer
 
growth under the action of a continuously delivered anticancer
 
drug. The therapeutic 
objective is to obtain the nature of the
 
control agent that can drive the tumour population to a 
desired
 
level so as to decrease excessive usage of the drug and to keep
 
deviations of the 
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tumour population from the desired level to
 
a minimum. While the drug resistance which the 
key of the successful chemotherapy treatment did not consider. 
Tan et al., (2001) presented an optimal control of drug scheduling in cancer 
chemotherapy using a distributed evolutionary computing software solutions called “Paladin-
distributed evolutionary algorithm”. The simulation result for the problem with and without 
point constraints confirmed the effectiveness of the proposed approach by producing control 
policies of the drug scheduling in cancer chemotherapy. The proposed evolutionary 
optimisation methodology is capable to automatically find near optimal solution for complex 
cancer chemotherapy problem. However, this solution does not take into all patients’ 
situations as fixed parameters have been considered only.     
Liang et al, (2005) demonstrated an anticancer drug scheduling model with different 
toxic elimination processes. The author also presented a sophisticated automating drug 
scheduling approach based on evolutionary computation and computer modelling. Also Liang 
et al, (2006) further introduced a customised optimal control model of drug scheduling in 
cancer chemotherapy and a new adaptive elitist population based genetic algorithm (AEGA) 
to solve it. These solutions did not consider the drug resistance which is key for a successful 
treatment. There are many researchers carried on the work to find the optimum solutions 
using different control techniques for example (Optimal Control Problem (OCP)) (Costa, 
1992, Westman, et al., 2002, Basdevan, et al., 2004).   
Optimal control is the standard method for solving dynamic optimisation problems, 
when these problems are expressed in continuous time. Treatment of cancer disease process 
can be interpreted as the optimal control of a dynamic system. Evolution of the disease is 
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characterised by a non-linear, ordinary differential equation that describes the stage of the 
disease, by predicting the number of tumour cancer cells. 
Alexandru and Carmen (2003) presented an optimal control problem model of cancer 
chemotherapy drug scheduling, using a feedback adaptive neural network control. This 
method is valid for all classes of pharmacokinetical models. It has been proved that the 
feedback controller for drug scheduling approach is capable of automatically solving 
complex cancer chemotherapy problems in a realistic manner.  
Hassani and Naghihi (2010) presented an optimal control problem of chemotherapy 
drug scheduling doses for patients with progressive cancer. The optimal control problem is 
used to design an effective drug schedule to reduce the size of the tumours in a time optimal 
fashion. Performance evaluation of the proposed algorithm has been performed by simulating 
the mathematical model of tumour cells interacting with immune system. Although the 
dynamic model of ordinary differential equations was implemented for the simulation of 
dynamic environment and reward signal, showing the ability of reinforcement learning (RL) 
algorithms in solving optimal control problems was the main purpose.  
Even though there are many options of treatment for cancer patients such as surgery, 
chemotherapy, immunotherapy, radiotherapy and the combination of these options, all of 
them are not perfect treatments because cannot eliminate the cancer cells totally. The life 
expectancy of the cancer patients will be diminished due to the disease and quite possibly for 
the adverse effects of treatments as well. These treatment rules cannot in general provide a 
cure for cancer but may bring about remission that can later relapse (R. Webster, 2002). The 
effects of these treatments can vary from cancer to cancer and individual to individual, which 
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further complicates the situation for effective eradication of cancer in any given patient 
(Westman, et al, 2002).  All these models did not consider the cell compartments that means 
all the cells will be affected by the cancer chemotherapy treatment even the normal cells, so 
the normal cells needs some rest after a period of treatment in order to recover from the drug 
toxic effect to start the next cycle of treatment. 
The existing multi-drug cancer chemotherapy models are to control the growth of the 
tumour effectively and minimise drug resistance and toxicity. Using mathematical modelling 
helps us to design a model for tumour population to meet the requirements of the treatment, 
and to balance the benefits of the treatment. Different compartmental models based on the 
cells function are also existed and used to explore the effects of chemotherapy cancer drug 
throughout the period of treatment.  
2.4 Phase specific and Non-phase specific Treatment Models 
The most important challenge of cancer treatment is to maintain the normal 
physiological states of the patient’s body system during the course of different treatment 
schedules. This can be achieved by optimising chemotherapy treatment in such a way as to 
reduce tumour burden to a minimum level with minimum/acceptable toxic side-effects. The 
other factors considered in chemotherapy include the stage of the diseases, scheduling of the 
therapy and interaction of the drugs (Martin and Teo, 1994).  
The mathematical models of tumour responses for chemotherapy are widely used to 
predict the tumour responses and to design the drug dosages. The models are generally 
developed based on a set of differential equations. The purpose of using mathematical models 
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of cancer chemotherapy is to predict and control the course of the disease when a treatment is 
used.  
Mathematical models of cancer chemotherapy treatment are designed and implemented 
to predict and control the growth of the cancer cells and demonstrate the interactions between 
tumour and normal cells which can affect the outcome of the treatment and the ability for a 
tumour to recur (Martin and Teo, 1994, Barbolosi and Iliadis, 2000). These mathematical 
models can be categorised by the number of compartments, for example, in one compartment 
models for the chemotherapy treatment, the various types of cancer cells are thought of as 
single types of cancer cells which are all included in the growth fraction. 
Martin and Teo (1994) used control parameterisation and analytical gradients to find 
optimum drug schedules with all many constraints related to toxicity, drug concentration and 
tumour growth. Panetta (1999) developed a model to show how to determine an effective 
treatment, how combination of chemotherapy should be delivered and how this model may 
help to develop more effective cancer chemotherapeutic treatments. These models designed 
for limited number of drug combination which is made the chance of the drug resistance 
exist. 
Barbolosi and Iliadis, (2000) considered the single compartment model for the cancer 
chemotherapy treatment and two compartments are used for the pharmacokinetics for the 
drug concentrations as well as a model that considers white blood cells to impose a toxicity 
constraint on the concentration of drugs administered. The model based on optimal drug 
doses in order to provide for greater cancer cell reduction, while limiting the risk of 
unacceptable toxicity.  
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Tes and co-workers (2005) further introduced a customised optimal control model of 
drug scheduling in cancer chemotherapy and they used genetic algorithm to solve it. The 
result of the first model shows that the drug should be injected towards the end of the 
chemotherapy period. In contrast, the second model shows that the quiescent cells are not 
remaining at the same level during the therapy and the rest of the cells do not directly 
affected by the drug.  
An optimal control model of drug scheduling in cancer chemotherapy was introduced by 
Tes, et al, (2007) and it was optimised by using genetic algorithm (GA). Liang, et al, (2008) 
used a variant of GA, called adaptive elitist population based GA to design the chemotherapy 
drug scheduling for non-specific cancer treatment. In the aforementioned works, single 
objective evolutionary optimisation approaches were used, mainly to minimise the cancerous 
cells during the whole period of chemotherapy treatment. 
 In conventional single objective optimisation approaches, the individuals/solutions converge 
to a single point as the algorithms proceed. Optimal performance according to tumour 
eradication/cell reduction often yields unacceptably high doses or high toxic side effects.  
As mentioned earlier, in chemotherapy drug scheduling problem, tumour 
eradication/reduction and toxic side-effects are always found in conflict to one another and it 
is never possible to minimise both the objectives simultaneously with conventional single 
objective optimisation techniques. Optimal performance according to one objective often 
yields unacceptably low performance in other objective domain, creating the need for 
compromise. To deal with multiple conflicting objectives and constraints, a relatively new set 
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of algorithms has emerged, commonly known as multi-objective evolutionary algorithms 
(MOEAs) (Deb, 2001).  
McCall and Co-worker (2008) also utilised multi-objective evolutionary algorithms to 
design chemotherapy drug scheduling where drug doses and toxic side effect were set as 
constraints. A set of solutions were designed trading-off two design objectives; tumour 
eradication and patient survival time (PST). In their work, some important treatment 
parameters, such as, maximum cumulative drug doses, maximum allowable size of the tumour 
and toxic side-effects were used as constraints in the GA optimisation process that resulted an 
effective drug scheduling at the end. 
In all preceding works, the chemotherapy drug scheduling was designed for non-
specific tumour growth model and treatment where toxicity was set as constraint. Moreover, 
no control system/strategy was used to design the drug doses or scheduling. Motivated by the 
success and effectiveness of multi-objective optimisation in biomedical engineering and 
systems biology, the current researchers utilise its potential in designing chemotherapy drug 
scheduling for cell cycle specific cancer treatment as a first hand work.  
The simplest mathematical models which are commonly used in research for optimal 
control of cancer chemotherapy assume the entire cell cycle as one compartment (Martin, 
1992; Swierniak, 1994). In many cases, these single compartment models are proved to be 
inadequate and do not seem realistic due to the over simplified nature of the model compared 
to actual biological system. The actions of the chemotherapy treatment agents are based upon 
an understanding of the cell cycling mechanisms. The cell cycle is modelled in the form of 
multiple compartments which describe different cell phases or combine phases of the cell 
cycle into clusters. In general, the cell cycle comprises of five stages which should pass 
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thorough dependents of the type of the cell as shown in Figure 2. 2. A brief description of 
different stages is given below (Dua, et al, 2008; Martin and Teo, 1994): 
 G1: Post mitotic gap, the cell prepares for DNA synthesis. 
 S: DNA synthesis takes place in preparation for cell division (many anticancer drugs 
act by interfering with DNA at this stage, causing cell death). 
 G2: Pre-mitotic gap, specialised proteins and RNA are synthesised in preparation for 
cell division. 
 M: Mitotic phase, cell division takes place to produce two identical daughter cells. 
 Go: Resting phase, cell is quiescent, viable but unable to divide. The cell cycle is a 
chain of phases that both normal and cancer cells undergo from their birth to death.  
 
Fig. 2.2 Schematic diagrams of different phases of cell cycle 
In all of these phases there are a number of checkpoints that the cell must pass through to 
insure the integrity of the DNA. If the cell fails to meet the necessary requirements at the 
various checkpoints, the cell either repairs or destroys itself, a process referred to as apoptosis 
or programmed cell death. Should one of these checkpoint mechanisms fail, the result can be 
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a  malignant cell that has mutated from a normal cell and thus is a germ or initial proliferating 
cancerous cell which may potentially develop into cancer. 
 To explain tumour response more realistically, multi-compartment models have been 
proposed and used in optimal chemotherapy. Of the multi-compartment models, the simplest 
and at the same time most natural ones, are two/three sometime more compartment models; 
which divide the cell cycle into two/three compartments (Swierniak, et al., 1996). 
In (2005), Swierniak considered a specific class of mathematical models based on cell cycle 
kinetics which are used to describe and improve cancer chemotherapy treatment protocols in 
phase-specific. This type of models contains a two compartmental model of single drug 
chemotherapy, three compartmental models of multi-drug therapy combining blocking and 
killing actions, and recruitment from quiescence together with killing action, as well as more 
general multi-compartmental model with many drugs. Moreover, this property is crucial for 
elimination of singular controls from candidates for optimality. 
The study of Minaya Villasana (2010) extended a previous mathematical model of 
cancer cytotoxic chemotherapy, which considered cycling tumour cells and interactions with 
the immune system, by incorporating a different type of drug: a cytostatic agent. The effect of 
a cytostatic drug is to arrest cells in a phase of their cycle. In consequence, once tumour cells 
are arrested and synchronized, they can be targeted with a cytotoxic agent, thus maximizing 
cell kill fraction and minimising normal cell killing. The goal is to incorporate the new drug 
into the chemotherapy protocol and devise optimal delivery schedules. The author concluded 
that the approach can serve as a valuable decision support tool for the medical practitioner 
facing the complex problem of designing efficient combined chemotherapies 
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In these models the G2 and M phases are combined into one compartment. In the two 
compartment model G0, G1 and S form another compartment while different three 
compartment models arise by separating the synthesis phase S or the dormant stage G0 for the 
three-compartment model. The purpose of this division is to effectively model various drugs 
used in chemotherapy like killing agents, blocking agents or recruiting agents (Swierniak, et 
al., 2003a).  
Two compartment models of cancer cells population have been considered in their 
work (Kozusko, et al., 2003) which includes transition rates between proliferating and 
quiescent cells as non-specified functions of the total population. The cancer cells in the first 
subpopulation are active and known as proliferating cells, while cells in the second group are 
mainly quiescent (inactive). In this dynamic system, proliferating and quiescent 
subpopulations can convert into each other; both subpopulations are affected by the natural 
death rate, and the proliferating subpopulation is also affected by the proliferating rate. Two 
cell population dynamics can be expressed in a mathematical model framework in terms of 
ordinary linear differential equations (Swierniak, et al., 1996, Dua, et al., 2008).  
  Kozusko and co-workers in (2003) has designed a model which predicts that the 
number of proliferating cells that increase with the total number of cells. The method which 
has been used to implement for obtaining the size of proliferating and quiescent 
subpopulation, based on postulated total cell population kinetics. The model has improved the 
effectiveness of the chemotherapy treatment but there are some weaknesses for this model 
such as the drug resistance. 
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Dua and co-workers in (2008) have presented two models for cancer chemotherapy. 
The first model describes the entire cell cycle as a uniform entity, where all the cells 
contained in a tumour are of the same type and consists of one compartment such that the 
effect of anticancer agents is at the same level within all the cells. The second model 
considers the cell cycle which consists of more than one compartment to take into account the 
type of cells that are affected by the drug.  
The result of the first model shows that the drug should be injected towards the end of 
the chemotherapy period. In contrast, the second model shows that the quiescent cells are not 
remaining at the same level during the therapy and the rest of the cells do not directly 
affected by the drug. The tissue, in general, contains three different types of cells: the 
proliferating cells, the quiescent cells and the dead cells.  
 
Fig. 2.3 The functional within tissue 
So a cell compartment model containing aforementioned types of cells as shown in Figure 2. 
3, is often considered to explain cancer tumour growth more clearly. The proliferating part 
contains actively dividing cells whereas quiescent part is inactive cells, but capable of 
dividing if a certain stimulus is given. The dead cells are unable to divide because they have 
completed their life cycle.  
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Fig. 2.4 Two compartments functional within tumour tissue 
Figure 2.4, shows a two compartment model where   (Proliferating) presents the 
combination of the first four stages of the cell cycle as mentioned earlier                
and   (Quiescent cells) indicates stage 𝐺 . The parameters m and b express the immigrants 
between the proliferating cells and quiescent cells respectively. Here    is indicates to the 
growth rate of cycling cells and   is the natural decay of the cycling cells. 
A number of models have been developed and used to characterise the evolution and 
effects of treatment on cancer by dividing the tumour into number of compartments (phase-
specific) as considered in (Ochoa and Burke, 2007, Liang, et al., 2008). Evolutionary 
algorithms have been extensively applied to design the chemotherapy drug scheduling for 
cancer treatment. Single objective evolutionary optimisation approaches were used, mainly to 
minimise the cancerous cells throughout the whole period of chemotherapy treatment. 
McCall, et al., (2008) designed chemotherapy drug scheduling using genetic 
algorithms where tumour eradication was used as the objective function, to be minimised. In 
their work, other important treatment parameters, such as, maximum drug doses, maximum 
cumulative drug doses, maximum allowable size of the tumour and toxic side effects were 
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used as constraints in the GA optimisation process that resulted an effective drug scheduling at 
the end. 
In another work Petrovski, et al., (2004), used a relatively new bio-inspired algorithm, called 
particle swarm optimisation to design chemotherapy drug scheduling using aforementioned 
design objective and constraints.  
A linear model presented by Adam and Panetta (1995) describes the administration of 
anticancer drug for cell cycling specific chemotherapy. Panetta (1999) developed a model to 
show how to determine an effective treatment, how combination of chemotherapy should be 
delivered and how this model may help to develop more effective cancer chemotherapeutic 
treatments. Two compartment models of cancer cells population have been considered in 
their work which includes transition rates between proliferating and quiescent cells as non-
specified functions of the total population but the number of compartments was limited so 
that is made the combination of the drugs limited as well. 
Kozusko (2003) designed a model which predicts that the number of proliferating 
cells that increase with the total number of cells. Basse et al., (2004) presented a method to 
model a population of cells and the effects of cancer therapy. The authors initially developed 
a theoretical one compartment size structured cell population model and investigated its 
asymptotic steady size distributions (SSDs), size was a generic term, but to obtain a realistic 
steady size distributions in one compartment model, the size was chosen to be DNA content 
and then devised a multi-compartment mathematical model for the cell division cycle where 
each compartment was related to a distinct phase of the cell cycle.  
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Swierniak in (2003b) demonstrated three models based in the cell cycle, those models 
considered the two compartment model during cell division constitutes. In all models the 
cumulative effect of the killing agent is used to model the negative effect of the treatment on 
healthy cells. Swierniak in (2005) combined models that so far have been analysed and 
implemented separately, taking into account both the partial sensitivity of the resistant 
subpopulation of gene amplification and drug specificity in chemotherapy in their different 
aspects.  
Stengel and co-workers in (2002) introduced control histories that minimise a 
quadratic cost function are generated by numerical optimization over a fixed interval time. 
Tradeoffs between cost function weighting of pathogens, organ health, and use of 
therapeutics are evaluated. Optimal control solutions that defeat the pathogen and preserve 
organ health are demonstrated for four different approaches to therapy. 
The chemotherapy treatments in these models either represent a continual kill where a 
fixed percentage of cells are killed at every cycle of treatment, or a reduced kill in which the 
fraction of cells is reduced dependent on the number of treatments cycle given. Monitoring 
the cancer cells can be done by tracking the total number of the cancer cells, while also 
tracking the subpopulations within it.  
Many researchers have developed mathematical models of tumour growth and cell 
killing by considering the administration of drugs as well as drug resistance (Ledzewicz, et 
al., 2009; Tes, et al., 2007; Woderz, 2005). They have also developed mathematical models 
for drug scheduling and toxicity elimination based on ordinary differential equations. As 
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mentioned earlier, the optimal cancer chemotherapy protocols are chosen to minimise the 
number of the tumour cells with less toxic side-effects by different methods.  
Recently, a model presented by Kozusko and Bajzer to accommodate the Gompertz 
function within the context of two compartment cell population dynamics and the study 
predicted an analytical solution for the evolution of two kinds of subpopulations within the 
tumour. They lately modified their model to include the presence of anti-mitotic drugs, when 
the drugs decrease the reproduction constant and increase the death rate of the proliferating 
subpopulation. The drug amount is considered to be constant in their study.  
Kozusko, (2003) implemented his model which predicts that the number of 
proliferating cells increases along with the total number of cells, but the proliferating fraction 
appears to be a continuously decreasing function. Due, et al., (2008), presented, two models 
for cancer chemotherapy, the first model describes the entire cell cycle as a uniform entity, 
where all the cells contained in a tumour are of the same type and consists of one 
compartment such that the effect of anticancer agents is at the same level within all the cells, 
the second model considers the cell cycle which consists of more than one compartment to 
take into account the type of cells that are affected by the drug.  
Mathematical models of tumour growth and response of tumour with anticancer drugs are 
crucial in the design and developments of new drugs and their scheduling. For example, the 
models in vivo and vitro may take months to run its course, and in some cases, years. It’s 
often quicker and cheaper to formulate a mathematical model and simulate it on silico than 
perform -laboratory experiments or clinical trials (Martin and Teo, 1994).  
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Finally, the first part of the analytical and modelling implementation shows that the all 
cell in the tissue considered as one compartment so when the drug be injected all the cells 
will effected by chemotherapy during the period of treatment. In contrast the second part of 
the analytical and modelling shows that the division of the tissue based on the cells behaviour 
does not directly affected all the cells by the drug. The quiescent cells are not remain same 
during the therapy that means the quiescent cells will be stimulate by the cancer drug 
chemotherapy and become active or proliferating cells and the normal cells will maintained. 
2.5  Combination of Chemotherapy Regimen 
The main aim of chemotherapy treatment, as motioned early in many places is to 
eradicate or minimise the cancer cells with minimum toxic side effects. Very often, cancer 
cells grow resistance to a drug if it continues for a long time and resistance to drug causes 
failure to treatment in most cases. When the chemotherapy treatment failure occurs, the drugs 
will need to be changed. The combinations of multiple drugs can decrease the drug resistance 
(Martin and Teo, 1994).  
Toxic side-effects developed due to the infusion of chemotherapy drugs always pose a major 
challenge in drug scheduling. So drug doses and their cycles of intervals must be design in 
such a way as to make the treatment effective, i.e., eradicate the tumour with 
minimum/tolerable toxic side-effects. The actions of the chemotherapy drugs (agents) are 
based upon an understanding of the cell cycling mechanisms.  
Researchers have developed mathematical models for drug scheduling and toxicity 
elimination based on ordinary differential equations (Martin, 1992). The optimal cancer 
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chemotherapy protocols are chosen to minimise the number of the tumour cells with less 
toxic side effects by different methods. Martin and Teo, (1994) used control parameterisation 
and analytical gradients to find optimum drug schedules with all many constraints related to 
toxicity, drug concentration and tumour growth.  
The cancer chemotherapy treatment is used to minimise the number of cancer cells 
after a number of fixed treatment cycles with minimum toxic side-effects. Traditionally one 
or more drugs are infused to the body. The efficiency of the doses of the treatment is often 
measured as the interval of time from the start of therapy, until the end of treatment. 
Chemotherapy involving the use of cytotoxic anti-neoplastic agents remains an important 
strategy in the overall management of patients with malignant tumours.   
Drug transporters and drug metabolising enzymes play key roles like most therapeutic 
agents in determining the pharmacokinetics and overall disposition of anti-neoplastic agents 
in the body. Drug transport and metabolism enzymes also influence the toxic effects of both 
anti-neoplastic agents in target tumour cells and normal host tissues (Kivisto, et al., 1995). 
Many characteristics of anti-neoplastic drugs make the metabolism of these agents 
particularly significant. Several anti-neoplastics display the doses response curves and low 
therapeutic indices, and the toxicity that they produce can be severe and life threatening. 
In practice, multi-drug chemotherapy treatment is preferred to avoid or reduce the 
risks of resistance grown in cancer cells against the infused drug and thus make the treatment 
more effective. The development of drug resistance is one reason that drugs are often given in 
combination. Often, if a cancer becomes resistant to one drug or group of drugs, it is more 
likely that the cancer may be resistant to other drugs. 
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Multi-drug resistance is cross resistance to some structurally and functionally 
unrelated naturally derived drugs and is characterised by the occurrence of cross resistance to 
a broad range of structurally and functionally unrelated drugs. It is one of the most important 
causes of unsuccessful chemotherapy in cancer treatment. Some of tumours are initially 
resistant and never respond to drug treatment, where as others become resistant after a good 
initial response. 
Use of multi-drug chemotherapy increases the effectiveness of greater cell kill, 
decreases the chance of drug resistance and reduces any toxic side-effects. Liang, et al., 
(2007), integrated the (AEGA) and Iterative Dynamic Programming (IDP) algorithms to form 
a new memetic algorithm (MA) approach. The new MA is developed to solve the multi-drug 
chemotherapy with a local search algorithm IDP. Ochoa, et al., (2007) investigated the 
employment of evolutionary algorithms as a search mechanism in a decision support system 
for designing chemotherapy scheduling. 
  Liang and co-workers in (2008) renewed two drug scheduling models with different 
toxicity metabolism according to kinetics of enzyme catalyzed chemical reactions. The 
different drug toxicity metabolism described according to kinetics of enzyme-catalyzed 
reaction. The combinations of drug has high efficiency of maximising killing the tumour of 
cells by decreasing the resistance of the cancer drug chemotherapy, but each drug has its own 
toxic so that is means the chance of increasing the toxicity will rising. 
Multi-drug resistance (MDR) is one of the major factors in limiting the successful use of 
chemotherapy in cancer treatment Souslova, et al., (2004), Brandt, et al., (2006). A phenotype 
that is referred to as multidrug resistance was first described for chemotherapy resistant 
cancer cells that over expressed the drug efflux transporter P-glycoprotein (P-gp).  
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Abundo and Rossi in (1989) the proposed model to study the problem of the drug 
resistance by cancer cell populations when chemotherapeutic agents are used to control 
tumour growth. The differential equations are numerically integrated to simulate expected 
response to the chemotherapeutic strategies as a function of different parameters.  
 Westman, et al., (2002), presented a model to explores the role of drug resistance in 
the evolution of cancer subject to treatment with a single Cytotoxic agent. In (2004) Souslova 
proofed that some cells are more sensitive than other and hyperthermia is useful for 
eliminating MDR cells but the toxic bit high. 
Brandt and co-workers in (2006) presented a model that allows selecting drug 
resistant and drug responsive by prolonged treatment with the antiepileptic drug 
Phenobarbital at maximum tolerated doses. Tes, et al., in (2007) integrated the AEGA and 
Iterative Dynamic Programming (IDP) algorithms to form a new mimetic algorithm (MA) 
approach. The new MA is developed to solve the multi-drug chemotherapy with a local 
search algorithm IDP.  
Ochoa (2007) investigated the employment of evolutionary algorithms as a search 
mechanism in a decision support system for designing chemotherapy scheduling. Liang, et 
al., (2006) renewed two drug scheduling models with different toxicity metabolism according 
to kinetics of enzyme catalyzed chemical reactions. The different drug toxicity metabolism 
described according to kinetics of enzyme-catalyzed reaction. 
 In such case (multi-drug chemotherapy), the doses must be optimised to trade-off 
between the beneficial and adverse side-effects of the treatment. Since the beneficial and 
adverse side-effects are inherently found to be in conflict, conventional methods or single 
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objective optimisation techniques can hardly provide any suitable solution in multi-drug 
chemotherapy scheduling problem. 
2.6 Drug Resistance: Mechanism and Implications  
The chemotherapy drug resistance occurs when the cancer cells does not responding to a 
therapy, the cancer cells become resisting to the effects of the chemotherapy. This has been 
mentioned in many occasions as “cancer chemotherapy failed” (Martin and Teo, 
1994). When this occurs, the drugs will need to be changed. There are several possible 
reasons for chemotherapy resistance (www.chemocare.com, 2011). 
 Some of the cancer cells that are not killed by the chemotherapy mutate (change) and 
become resistant to the drug.  Once they multiply, there may be more resistant cells than 
cells that are sensitive to the chemotherapy.  
 Gene amplification:  A cancer cell may produce hundreds of copies of a particular gene.  
This gene triggers an overproduction of protein that renders the anticancer drug 
ineffective.  
 Cancer cells may pump the drug out of the cell as fast as it is going in using a molecule 
called p-glycoprotein.  
 Cancer cells may stop taking in the drugs because the protein that transports the drug 
across the cell wall stops working.  
 The cancer cells may learn how to repair the DNA breaks caused by some anti-cancer 
drugs.  
 Cancer cells may develop a mechanism that inactivates the drug. 
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The development of cancer chemotherapy drug resistance is one reason that drugs are often 
given in combination.  This reduces the incidence of developing resistance to any one drug.  
Often, if the cancer cells become resistant to one drug or group of drugs, it is more likely that 
the cancer cells may be resistant to other drugs.   
A number of different mechanisms may contribute to chemotherapy resistance. The basic 
mechanism of drug resistance or transport mediated resistance is due to the decreased 
concentration of the active drug in target cells. Because of decrease drug uptake or increased 
drug efflux across tumour cell membranes, and is activation of cellular ant-apoptotic defence 
(Thomas, et al., 2002, Souslova, et al., 2004, Triller, et al., 2006).  
Mechael and Gottesman in (2002) introduced a great knowledge about mechanisms of drug 
resistance in cancer cells, Figure 2.5. Regardless of the development of new targeted 
anticancer therapies, mechanisms that have evolved in mammals to protect cells against 
cytotoxic compounds in the environment will continue to act as obstacles to successful 
treatment of cancer. Even though, all these explorations about the cells mechanisms but still 
the behaviours of cancer cells not known as the research carrying on to discover more about 
it.   
One of the most known mechanisms is the over expression of P-glycoprotein (P-gp), is a part 
of larger family of efflux transporters. P-glycoprotein is localised in numerous tissues 
throughout the body and plays an important role in the disposition of many xenobioutics. The 
contribution of P-glycoprotein mediated drug transport is being evaluated in early drug 
discovery stages, particularly for compounds targeted to the central nervous system. 
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Fig. 2.5, Mechanisms of drug resistance in cancer cells, (Mechael and Gottesman, 2002).  
A phenotype that is referred to as multi-drug resistance was first described for chemotherapy 
resistant cancer cells that over expressed the drug efflux transporters P-glycoprotein (P-gp). 
In Abundo (1989) proposed procedure to simulate different chemotherapeutic strategies. 
Westman, et al., (2002) presented a model to explore the role of drug resistance in the 
evolution of cancer subject to treatment with a single cytotoxic agent.  
In Souslova, 2004, Souslova proofed that some cells are more sensitive than other and 
hyperthermia is useful for eliminating Multi-Drug Resistance MDR cells. Brandt, et al., 
(2006) presented a model that allows selecting drug resistance and drug responsive by 
prolonged treatment with the antiepileptic drug Phenobarbital at maximum tolerated doses.  
Tes, et al., (2007), integrated the AEGA and Iterative Dynamic Programming (IDP) 
algorithms to form a new mimetic algorithm (MA) approach. The new MA is developed to 
solve the multi-drug chemotherapy with a local search algorithm IDP. The models referred 
above have investigated the multi-drug resistance problem with different way in order to find 
the desired salutation, but didn’t consider the most effect factor which is the cell layers.  
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(Ledzewicz, et al., 2000) The resistant of cancer chemotherapy treatment is a universal 
problem and one of the main, although not the only obstacle to effective treatments. The hope 
is that the improvement in cancer chemotherapy drug scheduling sessions may delay the 
onset of drug resistance and thus give a higher life expectancy (Lobo and Balthasar, 2002). 
The authors presented a formulation and some preliminary analysis for two finite dimensional 
models using bang-bang controls for cancer chemotherapy taking into account drug 
resistance with respect to single and multiple killing agents.  
2.7 Summary of the Reported Study 
The cancer cells populations and the growth rate can be predicted by mathematical 
models to estimate the amount of the chemotherapy drug should be applied. One of the major 
aims of designing and implementing the chemotherapy drug scheduling models is to 
eradicate/minimise the tumour cells after a fixed treatment cycle with minimum side-effects. 
The understanding of the cell behaviours and division improves the treatment effectiveness. 
Some of the treatments models considered the cancer cells as one and many compartments 
which based on the mutations and behaviours of all cancer cells. The cancer cells divided for 
example; on four and eight compartments based on the sensitivity of the cancer cell to drug.    
The main challenges are to balance between the benefits and the side-effect of the 
chemotherapy cancer treatment. The proliferating cells at the tissue considered as active 
cancer cell and needs to be treated and divided to compartments called phase specific. The 
drug resistance has not been considered in some of the treatment models. The multi-drug 
regimen models are designed to overcome the limitations of the models which were designed 
to treat cancers.  
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2.8 Justification of this research 
The investigation of the cancer diseases has raised many factors that should be 
considered in designing and implementing optimisation models, which would have 
significant impact on effective of the cancer chemotherapy treatment.  Most of these factors 
have been investigated separately which has rise some limitations in the models developed 
earlier. Most of the cancer treatment models predict the cancer cells populations and the 
growth rate based on fixed rate (constant) which is may not applicable to all cases.  However, 
the accuracy of the cancer cells prediction in the patient’s body improves the impact of the 
treatment. 
Some of the cancer treatments models considered the cancer cells as a one compartment 
which means that the behaviours of all cancer cells are same (non-phase specific) and all of 
them treated by chemotherapy, which is required high doses of the drug and increases the 
side-effect as well. Moreover, some of the chemotherapy cancer drug models designed 
depends on the behaviours and mutation of the cancer cell on the tissue. The balance between 
all conflicts and constraints of cancer treatment is to maximise the cancer cell killing and 
reduce the side-effect of the treatment. However, these constraints need to consider more 
factors such as type of the cancer cells, stage of the disease, age and gender of the patient.  
Later on, many chemotherapy cancer drug models were designed and considered the 
proliferating cells on the tissue as active cancer cell and needs to be treated and divided to 
two compartments call phase specific. However, the division of the cancer cells based on 
their functions improves the chemotherapy treatment outcome. On the other hand, the drug 
resistance has not been taken in the account on these types of treatment models.   The multi-
drug regimen models are designed to avoid the weakness of the previous treatment models.  
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The cancer cells have been divided on four and eight compartments based upon the resistance 
of the cancer cell to one drug to another.  Furthermore, the cancer cells killing have been 
maximised with reduction of the toxic (side-effect) by using multi-drug chemotherapy cancer 
drug scheduling models.  
As motioned early, the main aim of chemotherapy treatment is to eradicate the tumour, 
if possible, or to reduce the tumour size to a minimum level with minimum toxic side-effects. 
But most chemotherapy drugs used in cancer treatment usually have narrow therapeutic 
indices, this means that the dose levels at which these drugs significantly kill the cancerous 
cells are close to those levels at which harmful toxic side-effects occur. Therefore, effective 
drug scheduling requires suitable balancing between the beneficial and toxic side-effects over 
a treatment period. Conventional clinical methods very often fail to find drug doses that 
balance between these two due to their inherent conflicting nature.   
In conclusion, it is recommended that researchers should consider all these factors 
related to optimisation of cancer chemotherapy, which has reviewed in this Chapter in order 
to avoid the limitations of proposed models. In contrast, the advantages of these models 
should also be considered to help the new researchers to developed relevant models. These 
advantages, for example; cell compartments, drug combinations and multi-drug resistance 
would clearly improve the desired outcome of the cancer treatment and the quality of life and 
care of the cancer patients. In the next Chapters, more details will be discussed including the 
results.  
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CHAPTER 3  
Methodology 
3.1 Background 
Many mathematical models have been developed to describe the growth and control 
of cancer cells. The main aspect of implementing those models is that they take into account 
the balance between the benefit and the side-effects of the treatment as well as the problems 
related to drug resistance. The mathematical model of such a system is generally represented 
by two or more ordinary differential equations which describe the growth of the cancer along 
with the effects of chemotherapy.  
The problem is generally modelled with a set of defferential equations, aiming to 
minimise the tumour size by the drug chemotherapy scheduling treatment. The extensive 
course of chemotherapy drug scheduling is designed to treat the patient rapidly and 
effectively to reduce the tumour cell after a number of fixed treatment cycles, in order to 
maximise the survival time of the patient. The purpose of using optimised mathematical 
models of cancer chemotherapy is to predict and control the course of the disease when a 
given treatment is being used. Figure 3.1 shows the scheme diagram for the system model.    
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Fig. 3.1 Scheme diagram for the system model 
3.2 Non Phase Specific 
The greatest challenge of cancer chemotherapy treatment is to maintain the normal 
physiological states of the patient’s body system during the period of treatment. This can be 
achieved by optimising chemotherapy treatment in such a way as to reduce/eliminate tumour 
burden to a minimum level with toxic side effects. The mathematical models are generally 
developed based on a set of defferential equations. The purpose of using mathematical 
models for cancer chemotherapy is to predict and control the course of the disease when a 
treatment is scheduled.  
 These mathematical models can be categorised by the number of compartments which has 
been considered. In one compartment models for the chemotherapy treatment, the various 
types of cancer cells are thought of as single types of cancer cells, which are all included in 
the growth fraction. 
Martin (Martin and Teo, 1994) introduced the well known differential equation for tumour 
response with chemotherapy drug as follows: 
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where        ,        and   are transformed variables, growth speed of the cancer cells, cells 
killed per unit time per unit drug concentration, drug concentration at the tumour site, 
threshold level of drug concentration and Heaviside step function respectively. 
Equation       describes the net change in tumour cell population per unit time. The first 
term in the right-hand side of       describes the increase in cells due to cell proliferation and 
the second term describes the decrease in cells due to the drug. The parameter (λ) is a positive 
constant related to the growth speed of the cancer cells and ( ) is the proportion of tumour 
cells killed per unit time per unit drug concentration, which is assumed to be a positive 
constant. Equation (3.2) is a Heaviside step function and the implication of it is that there is a 
threshold of the drug concentration level,    below which the chemotherapy drug cannot kill 
the tumour cells (Due et al., 2008).  A transformed variable    is inversely related to the mass 
of the tumour,   as:  
                                                                                                                                            
        
where    is the initial tumour cell population, which is assumed 10
10
 at the beginning of the 
treatment. The values of  ,   and   used in this work are set at         ,          and 
   respectively (Liang et al., 2008). The drug concentration is modelled using another 
differential equation as follows:  
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where   is the rate drug delivery and    is the biochemical character of the drug which is 
related to the half-life of the drug as:         . Equation       describes the net increase in 
the drug concentration at the cancer area. It is assumed that the drug is delivered by infusion, 
and there is an instantaneous mixing of the drug with plasma, as well as an immediate 
delivery of the drug to the cancer area. These assumptions represent approximations based on 
the relative amount of time it takes for the aforementioned activities to occur with respect to 
the total amount of time over which the treatment is administered. The value of   is set at 
     (Due et al., 2008). In order to kill the cancerous cells, the chemotherapy drug 
concentration at tumour site should be more than 10. The cytotoxic chemotherapy drug may 
cause adverse toxic side effects if the doses are not controlled properly. In order to avoid 
unbearable toxic side effects, the drug concentration, during the whole period of treatment 
should not exceed 50. The limiting values of drug concentration as suggested by many 
researchers are as follows (Due et al., 2008):    
                                                                                                                                                
Solving equation (3.4) gives: 
         
     
 
 
                                                                                                                              
where    is a constant, related to the increase of drug concentration at the tumour site. 
Finally, the toxicity is modelled as: 
   
  
                                                                                                                                             
here   is a constant, set to 0.4 (Due et al., 2008). Equation (3.7) describes the level of toxicity 
inside the patient’s body after applying the drug dosage, which relates the cumulative drug 
toxicity to the drug concentration. It is worth mentioning that the cumulative effect is the 
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integral of the drug concentration over the period of exposure. The maximum toxicity should 
not exceed 100 during the whole period of treatment, suggested by researchers as (Liang et 
al., 2008): 
                                                                                                                                                         
Solving equation (3.7) and substituting       gives: 
      
 
      
    
    
    
  
                                                                                                        
 Where    is a constant. Using equations (3.6), (3.9) and solving (3.1) gives: 
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The first term of equation (3.9) shows the rate of tumour growth without treatment 
which appears to follow Gompartz growth model, as indicated by the parameter  . The 
constant     represents the time response of the cells reduction. So if     is small, the response 
will be faster, otherwise the response will be relatively slower. The second term of equation 
(3.10) represents the drug doses     , which affect the rate of cells killing where parameter β 
is threshold level of drug concentration. The last term also represents the cell reduction due to 
drug that becomes effective after some time as indicated by the parameter γ, which is drug 
decay.  
3.3 Phase Specific  
The tissue, in general, contains three different types of cells: the proliferating cells, the 
quiescent cells and the dead cells. So a cell compartment model containing the aforementioned 
types of cells, as shown in Figure 3.2, is often considered to explain cancer tumour growth 
more clearly. The proliferating part contains actively dividing cells whereas the quiescent part 
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is inactive cells, but ones capable of dividing if a certain stimulus is given. The dead cells are 
unable to divide because they have completed their life cycle. Figure 3.2 shows a two-
compartment model where   (Proliferating) presents the combination of the first four stages of 
the cell cycle, as mentioned earlier                and   (Quiescent cells) indicates 
stage 𝐺 .  
The parameters   and   express the immigrants between the proliferating cells and quiescent 
cells respectively. Here    indicates the growth rate of cycling cells and   is the natural decay 
of the cycling cells. Based on clinical evidence, the population of proliferation and quiescent 
cells at the tumour site are assumed to be      and     at the time of diagnoses. For  a two 
compartment model, it is assumed that 80% of the cell population is quiescent while the 
remaining     is active proliferating cells (Dua et al., 2008). 
 
Fig. 3.2 Two functional compartments within tumour tissue 
A number of differential equations used to build a two compartment model of cancer 
chemotherapy treatment are explained briefly. The first equation predicts the rate of change of 
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proliferation cells population at the tumour site during the treatment, as follows (Dua et al., 
2008): 
  
  
                                       
                                                                                                                                                    
where   and   represent population of proliferating and quiescent cells. Here parameters 
            indicate the rate of growth of proliferation cells, immigrant from cycling to 
quiescent cells, and natural death of cycling cells respectively. A variable      indicates the 
effects of the drug on the tumour cell, which is the rate of cell killing per unit drug. Equation 
(3.12) describes the rate of change of cell population in the quiescent compartment of the 
tumour site during the period of treatment.  
  
  
                                                                                                                             
   The anticancer drugs affect both tumour cells and normal cells. To reduce the toxic side 
effects of chemotherapy treatment, the population of normal cells should be maintained as 
high as possible during the whole treatment period. A logistic equation is used to describe the 
effect of chemotherapy drug on normal cells, as expressed by equation (3.13) below: 
  
  
       (  
    
 
)                                                                                                               
        
     Here      indicates the normal cells population whereas    and    present the growth rate 
of the normal cells and the carrying capacity of normal cells respectively.      is the initial 
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value of normal cell population at the beginning of the treatment. Equation (3.14) shows the 
rate of change of drug concentration at the tumour site during the treatment cycle. 
  
  
      γ                                                                                                                         
   where      is the amount of drug doses to be infused to the patient’s body and    is drug 
decay, which is related to the metabolism of drug inside the patient’s body. It is noted that the 
drug concentration      at the tumour site should remain within the limit as suggested by 
equation (3.15) in order to make the chemotherapy treatment effective (Martin and Teo, 
1994).  
                                                                                                                                                 
Equation (3.16) shows the relationship between drug concentration at the tumour site and cell 
killing rate. 
                                                                                                                                                                       
  where    is a constant related to the effect of drug concentration on cell killing. Equation 
(3.17) shows the relationship between the level of toxicity and drug concentration at the 
tumour site during the treatment period. 
  
  
                                                                                                                                             
             
where      is the level of toxicity developed inside the patient’s body due to the 
chemotherapy drug and parameter   indicates the rate of elimination of toxicity. The level of 
toxicity should be controlled and kept within a tolerable range. The normal cells are 
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adversely affected by the drug. To limit the toxic effect, the number of normal cells should be 
maintained up to a certain value. Equation (3.18) expresses the limiting values of normal cell 
which should be maintained throughout the period of treatment.  
                      [   ]                                                                                                                                                                                           
The parameter      indicates the minimum number of the normal cells at the tumour site. 
Using the above equations, a Simulink (The Mathworks, Inc., 2008) model was developed 
with parameters and values as illustrated in Table 3. 1. 
Table 3.1:  Parameters of Patient Model (Dua et al., 2008) 
Parameters Values 
a The rate of growth Proliferating (cancer) cells 0.5 day
-1
 
m The mutation rate of proliferating cells to quiescent cells 0.218 day
-1
 
n The natural end of the cycling cells 0.477 day
-1
 
b The mutation rate of quiescent cells to proliferating cells 0.05 day
-1
 
  The rate of normal (healthy) cell growth 0.1 day-1 
Κ The carrying capacity of  normal cell 109 cells 
P The proliferating cells population 2x10
11
 
Q The quiescent (inactive cancer cells) cells population 8x10
11
 
Y The normal cells population 10
9
 
      The limitation of normal cells 10
8
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3.4 Four Compartments 
This work focuses on multi-drug chemotherapy scheduling where two drugs are used 
and, for ease of discussion, those drugs are indicated by A and B, respectively. For two-drug 
chemotherapy treatment, a tumour model consisting of four compartments, as shown in 
Figure 3.3. The sub-population 𝑆    presents the cells which are sensitive to both drugs A 
and B. The cells which are totally resistant to drug A are expressed by       while       
indicates the number of cells resistant to drug B.        presents the cells which are doubly 
resistant for all drugs (Martin and Teo, 1994). The chemotherapy drug A is effective on two 
sub-populations; 𝑆    and      whereas the chemotherapy drug B is effective on the two 
sub-populations; 𝑆    and     .  The sub-populations of cancer cells that are not resistant to 
drug A are killed only when the concentration of drug A,     is maintained above the 
threshold drug concentration     . Similarly the drug concentration of drug B should be 
raised above the threshold drug concentration      to kill cells which are not resistant to this 
drug. The two sub-populations         increase by the constant rate,          , which 
are both less than 1. The total resistance cells for both drugs arise from two directions and 
two stages of process parallel, as illustrated in Figure 3. 2.  
 
Fig. 3.3 Four compartments for multi-drug 
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The drugs A and B are assumed to be non-cross resistant. The proportions of cells killed by 
drug A from the sensitive and resistant sub-population S and NB are the same. Similar things 
apply TO drug B (Martin and Teo, 1994).  
  
  
 λ                                 
                                                                            
where   represent population of the cancer cells. Here parameter    relates to the rate of 
growth of cancer cells,    the rate of cancer cells killed by drug unit. Parameters 
                relate to the drug concentration for drug A, drug B, threshold for drug A and 
threshold for drug B, respectively. The parameters               expressed the cells 
resistant to drug A, the cells resistant to drug B and doubly resistant cells respectively. 
Equation (3.20) describes the sensitive cell for all drugs (Martin and Teo, 1994). 
  
  
 λ                                                                              
Equation (3.21) describes the resistance cells for drug A, where Equation (3.22) represents 
the resistance cells for drug B and Equation (3.23) shows the cells which are doubly resistant.  
   
  
 λ[               ]                                                              
   
  
 λ[               ]                                                             
    
  
 λ[              ]                                                                                                       
where       is the Heaviside step function defined as:   
     {
            
           
}                                                                                                                                   
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The initial sizes of the cell sub-populations are: 
        𝑆    𝑆                                                                                    
The consequence of this model is that at every instant time 
     𝑆                                                                                                                           
Equations (3.27) and 3.28) show the rate of change of drug concentration for both drugs at 
the tumour site during the treatment cycle. 
   
  
                                                                                                                      
   
  
       γ                                                                                                               
  Where                 are the amounts of drug doses to be infused to the patient’s body 
and    is drug decay, which is related to the metabolism of drug inside the patient’s body. It is 
noted that the drug concentration                at the tumour site should not exceed the 
limit as suggested by equation (3.29) (Martin ad Teo, 1994).  
                                                                                                                                                                                                      
Equations (3.30) and (3.31) show the relationship between levels of toxicity and drug 
concentration at the tumour site during the treatment. 
   
  
                                                                                                                        
   
  
                                                                                                                        
  CHAPTER 3 
 
56 
 
    where                are the level of toxicity for both drugs developed inside the 
patient’s body due to chemotherapy drug, and parameter   indicates the rate of elimination of 
toxicity. Using the above equations, a Simulink model was developed with parameters and 
values as illustrated in Table 3.2 (Martin and Teo, 1994).  
Table 3.2: The parameters of the simulink model (Liang, et al, 2008) 
parameters value parameter value 
   
   
   
   
   
   
     
     
0.4 day
-1 
0.5 day
-1 
0.008 
0.01 
0.32 day
 
0.27 day 
10 D 
10 D 
    
    
     
   
   
  
𝑆  
0 
0 
0 
0.0084 day
-1
 D
-1
 
0.0076 day
-1
 D
-1 
- 
4.60517X10
11
 
3.5 Eight Compartment Model 
For multi-drug chemotherapy treatment, three non-cross resistant drugs are denoted 
by A, B and C, in general, for ease of discussion. A tumour model consisting of eight 
compartments is considered, as shown in Figure 3.4, to examine the pharmacokinetic and 
pharmacodynamic effects of three drugs in the  patient’s body during the treatment. The sub-
population 𝑆    represents the cells which are sensitive to all drugs A, B and C. 
                     expressed the cells totally resistant to drugs A, B and C 
respectively. The        presents the cells which are doubly resistant for drugs A and B. 
       and        indicates the cells which are doubly resistant for drug A and C, and B and 
C respectively (Martin and Teo, 1994). The chemotherapy drug A is effective on four sub-
populations: 𝑆   ,     ,       and       . While the chemotherapy drug B is effective on 
the four sub-populations: 𝑆   ,     ,       and      , and, on the other hand, the 
chemotherapy drug C is effective on the four sub-populations, 𝑆   ,     ,       and 
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      . The sub-populations of cancer cells that are not resistant to drug A are killed only 
when the concentration of drug A,     is maintained above the drug concentration 
threshold     . Similarly the drug concentration of drug B and C should be raised above the 
threshold drug concentration      and       to kill cells which are not resistant to these drugs. 
The three sub-populations             increased by the constant rate             , 
which are all less than 1 (Martin and Teo., 1994). The total resistance cells for all drugs arise 
from three directions in parallel, as illustrated in Figure 3.4. 
 
Fig. 3.4 Eight compartments for multi-drug 
The proportions of cells killed by drug A from the sensitive and resistant sub-population 
           are the same, similar to drug B and C (Martin and Teo, 1994). If    indicates the 
rate of growth of cancer cells and   ,    and    are the rate of cancer cells killed by drug 
unit. Equation 1 describes the sensitive cell for all drugs, where      {        
             } is the Heaviside step function. 
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 λ[             ]                        
                                                                   
Equation (3.33) represents the resistance cells for drug A and can be calculated for drugs B 
and C similarly.  
   
  
 λ[               ]                       
                                                                                                      
Equations 3.34, 3.35 and 3.36 are for deriving the cells which are doubly resistant.      
    
  
 λ[                   ]                                                       
    
  
 λ[                   ]                                                       
    
  
 λ[                   ]                                                      
The initial sizes of the cell sub-populations are: 
𝑆    𝑆                               
                                            
                  
The consequence of this model is shown in Equation 3.38 
     𝑆                                                                   
Now the rates of change of drug concentration                      for drugs at the 
tumour site during the treatment cycle are shown, where                       are the 
amounts of drug doses to be infused to the patient’s body and λ is the drug decay which is 
related to the metabolism of drug inside patient’s body. It should also be noted that all the 
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drug concentrations at the tumour site should not exceed the limit of 50, as suggested (Martin 
and Teo, 1994). 
   
  
                                  {     }                                                   
The following Equations show the relationship between level of toxicity and drug 
concentration at the tumour site during the treatment, where                      are the 
levels of toxicity for all drugs developed inside the patient’s body due to chemotherapy drug 
and parameter   indicates the rate of elimination of toxicity.  
   
  
                                           {     }                                            
where                      are the levels of toxicity for both drugs developed inside the 
patient’s body due to chemotherapy drug and parameter   indicates the rate of elimination of 
toxicity. Before the treatment starts, the number of cancer cells is set at 4.60517x10
11
, as used 
by many researchers in cell cycle specific cancer treatment (Tes et al., 2007). 
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3.6 PID Controller 
3.6.1 PID controller structure  
The controllers are widely used in many different applications, such as industry 
sectors and it has been proved that the use of controllers enhances the performance of the 
system and eliminates errors which could affect the outcome of the system. The controllers 
provide more functions and features, which may require adding equipment, such as sensors, 
to the system. These additions can add to the expense of the controller. For example, there are 
many types of controllers which may be applicable in one application but not in another. We 
have used one of these controllers, a proportional (P), integrative (I) and derivative (D) celled 
PID controller; where details will be reviewed in the next section. The PID algorithm is the 
most popular feedback controller used within the process industries (M. Willis, 1999). It has 
been successfully used in the past for many years. It is a robust, easily understood algorithm 
that can provide excellent control performance despite the varied dynamic characteristics of 
process plant. 
3.6.2 PID Integrated to the System  
The proposed optimal control model and the close loop of treatment delivery in 
Figure 3.5 shows that the feedback of drug concentration is provided to the controller to 
correct the errors. The drug dosage (which is the input) will affect the three outputs: toxicity, 
drug concentration and the cell’s population. 
The mathematical models of tumour responses for chemotherapy are widely used to predict 
the tumour responses and to optimise the control parameters. The problem is generally 
modelled with a set of defferential equations, the aim being to minimise the tumour size by 
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the drug chemotherapy scheduling. The extensive course of chemotherapy is designed to treat 
the patient rapidly to reduce the tumour cell after a number of fixed treatment cycles, in order 
to maximise survival time of the patients. 
 
Fig. 3.5 The schematic diagram of the Control Scheme 
The I-PD controller algorithm involves three separate parameters: the proportional, integral 
and derivate values. The proportional value gives a system control input (dosage of drug) 
proportional to the error, the integral value gives an addition from the sum of the previous 
errors to the system input (drug doses), and Derivative value gives an addition from the rate of 
change in the error to the system control input (drug doses). The weighted sum of these three 
actions is used to adjust the process via a control element, such as the position of a control 
value. 
Three objective functions were considered for the cancer drug chemotherapy. These are 
discussed below(Martin, 1992): 
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where χ1 is a changed variable which is inversely related to the mass of the tumour. The 
tumour mass is given by                  cells, and the initial tumour cell population set 
at 10
10
 cells (Martin and Teo, 1994). 
Equation (3.41) describes the net change in tumour cell population per unit time. The first 
term in the right- hand side of equation (3.41) describes the increase in cells payable to Cell 
proliferation and the second term describes the decrease in cells payable to the drug. The 
parameter (λ) is a positive constant related to the growth speed of the cancer cells and (κ) is 
the proportion of tumour cells killed per unit time per unit drug concentration, which is 
assumed to be a positive constant. 
   
  
                                                                                                                                            
Equation (3.42) describes the net increase in the drug concentration at the cancer site. The 
variable u  is the rate of the delivery of the drug, and the half-life of the drug is /)2ln( . It is 
assumed that the drug is delivered by infusion, and there is an instantaneous mixing of the 
drug with plasma, as well as an immediate delivery of the drug to the cancer site. These 
assumptions represent approximations based on the relative amount of time it takes for the 
aforementioned activities to occur with respect to the total amount of time over which the 
treatment is administered. 
   
  
                                                                                                                                           
Equation (3.43) describes the level of toxicity inside the patient’s body after applying the 
drug dosage, which relates the cumulative drug toxicity to the drug concentration. It is worth 
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mentioning that the cumulative effect is the integral of the drug concentration over the period 
of exposure.  
3.6.2.1 PID - Controller 
Many application processes are nonlinear and thus to be described mathematically. 
However, it is known that many nonlinear processes can be satisfactorily controlled using 
PID controllers, providing that the controller parameters are tuned well. Practical experience 
shows that this type of control has a lot of value, since it is simple and based on three basic 
behaviour types: proportional (P), integrative (I) and derivative (D). Instead of using a small 
number of complex controllers, a larger number of simple PID controllers are used to control 
simpler processes in an assembly application in order to automate the certain more complex 
process (Vukic, 2002). 
The PID controller is the most widely used controller and could be expected to be a backbone 
of many complex control systems (Astrom et al., 1993). Figure 3.6 shows a block diagram of 
the basic structure of PID controller, where the input is fed to the three gains of the controller. 
The input or set-point is added to the feedback of the system in order to eliminate the errors 
which may be generated during the initialisation of the system, to provide the suitable value 
to the system. 
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Fig. 3.6 Block diagram of PID controller 
The PID controllers use three type of basic parameters or modes, which are P - 
proportional, I -integrative and D-derivative. While proportional and integrative modes are 
also used as single control modes, a derivative mode is rarely used on its own in control 
systems. Combinations such as PI and PD control are very often used in practical systems. It 
can also be shown that the PID controller is a natural generalization of the simplest possible 
controller, the On-off controller (Vukic, 2002). Table (3.3) shows the PID controller effects. 
The PID, as mentioned earlier, has three separate parameters; tuning the system is done by 
adjusting these three parameters, Kp , Ki  and Kd , adding in various amounts of these 
functions to control how the system behaves. 
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Table 3.3: Shows the PID controller effects 
Effects parameters 
Parameter Rise time Overshoot Settling time Error at equilibrium 
Kp Decrease Increase Small change Decrease 
Ki Decrease Increase Increase Eliminate 
Kd 
Indefinite (small decrease or 
increase) 
Decrease Decrease None 
 
This section presents an investigation into the development of a model for optimal 
chemotherapy scheduling to control tumour growth with the PID controller in different 
structures. This model is based on the cells functions which are used to predict and control 
the tumour growth and other effects of treatment. We used the Genetic Algorithm (GA) 
method to optimise the parameter of PID controllers, which are applied with Martin model of 
drug concentration in order to maximise the cells killing and to minimise the toxic effects to 
increase the survival time of the patient.  
3.7 Genetic Algorithm (GA) for Optimisation 
The term Genetic Algorithm or (GA) describes a set of optimisation methods. GAs are 
adaptive methods, which can be used to search for the optimal solutions and optimisation 
complex problems. They are based on the genetic processes of biological organisms. Over 
many generations, natural populations evolve according to the principles of natural selection 
and survival of the fittest.  Genetic algorithms are able to evolve toward better solutions to 
real world problems, if they have been suitably encoded (Holland, 1975).  
GA is started with a set of solutions (represented by chromosomes) called population. 
Solutions from one population are taken and used to form a new population. This is 
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motivated by a hope that the new population will be better than the old one. Solutions which 
are selected to form new solutions (offspring) are selected according to their fitness - the 
more suitable they are, the more chances they have to reproduce (Marek, 1998).  
GAs works with a population of individuals, each representing a possible solution to a 
given problem. Each individual is assigned a fitness score according to how good a solution 
to the problem it is. The highly-fit individuals are given opportunities to reproduce by cross 
breeding with other individuals in the population. This produces new individuals as offspring, 
which share some features taken from each parent. The least fit members of the population 
are less likely to get selected for reproduction, and so die out (Chandy, 2006). 
A whole new population of possible solutions is thus produced by selecting the best 
individuals from the current generation, and mating them to produce a new set of individuals. 
This new generation contains a higher proportion of the characteristics possessed by the good 
members of the previous generation. In this way, over many generations, good characteristics 
are spread throughout the population. By favouring the mating of the more fit individuals, the 
most promising areas of the search space are explored. If the GA has been designed well, the 
population will converge to an optimal solution to the problem. Genetic Algorithm and Direct 
Search Toolbox extends the optimization capabilities in MATLAB and optimisation toolbox 
with tools for using genetic algorithms, simulated annealing and direct search. It is possible to 
use these algorithms for problems that are difficult to solve with traditional optimisation 
techniques, including problems that are not well defined or are difficult to model 
mathematically. These can also be used when computation of the objective function is 
discontinuous, highly nonlinear, and stochastic or has unreliable or undefined derivatives 
(Busetti et al., 2001, Chandy, 2006). 
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3.7.1 Genetic Algorithms 
GA as a stochastic optimisation algorithm is motivated by the mechanism of natural 
selection and evolutionary genetics (Holland, 1975). The basic element processed by a GA is 
a string formed by concatenating sub-strings, each of which is a numeric coding of a 
parameter. Each string represents a point in the search space. Selection, crossover and 
mutation are the main operations of a GA.  Selection directs the search of GA towards the 
best individual. In the process, strings with high fitness receive multiple copies in the next 
generation, while strings with low fitness receive fewer copies or even none at all. Crossover 
can cause the exchange of properties of any two chromosomes via random decision in the 
mating pool and provides a mechanism to produce and match the desirable qualities. 
Although selection and crossover provide most of the power skills, the solution space will be 
limited. Mutation is a random alternation of a bit in the string and assists in keeping diversity 
in the population (Holland, 1975, Goldberg, 1989).  
3.7.2 Multi-Objective Genetic Algorithm (MOGA) 
Multi-objective optimisation is the search for feasible solutions to problems 
comprising multiple objectives, which are often in conflict with one other. It can be defined 
as the problem of finding a vector of decision variables which satisfies constraints and 
optimises a vector function whose elements represent the objective functions. A multi-
objective optimisation problem can be expressed as:  
Find the vector   [             ]  which satisfies the m inequality constraints:       
             , the k equality constraints                      and optimises the 
vector function,      [                     ], where n is the number of objectives to 
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be considered,   [             ] is the vector of decision variables, p is the number of 
decision variables that comprise the complete solution. Practical problems are often 
characterised by several competing objectives. The multi-objective optimisation problem is 
the problem of simultaneously minimising the n components             of a possibly 
nonlinear vector function   of a general decision variable   in a universe  , where      
[                     ]. The problem usually has no unique, perfect solution, but a set of 
non-dominated solutions, known as the Pareto-optimal set (Deb, 2001).  
3.7.2.1 Algorithm description 
The MOGA optimisation process consists of a standard GA with multi-objective ranking, and 
with fitness sharing and mating restriction (Fonseca et al., 1993). A randomly selected 
population is generated within a specific range. Each individual of the population is evaluated 
with the objective functions. Then, each solution is checked for its domination in the 
population and a rank value is assigned to it. The ranking procedure can be explained through 
Figure 3. 7. For a two-objective minimisation problem, individuals that fall close to either the 
axes or origin of 2D objective space are better than those away from axes or origin. In the 
objective space some individuals may be found, such as, A, F, G, E etc., falling on the outer 
edge and close to the axes or origin and with one objective better than another, and form a set 
called the non-dominated solution set or Pareto optimal set. Individuals A, E, F, G etc. are 
called non-dominated because no other individuals provide better performance in the 
objective space.  On the other hand, individuals falling away from the edges, such as, B, C, D 
etc., are called dominated solutions since many individuals provide better performance than 
these in terms of both objectives. For example, individual A dominates individual B, and 
similarly B dominates C and C dominates D in the objective space in terms of both 
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objectives. Each individual is ranked according to their degree of dominance, i.e., number of 
individuals that are better than that in terms of both objectives. An individual’s ranking 
equals the number of individuals better than that in terms of both objectives plus one (See 
Figure 3. 7).  
To a solution    a rank    is assigned as:         where    is the number of 
solutions that dominate the solution. In this way, non-dominated solutions are assigned a rank 
equal to 1, since no solution would dominate a non-dominated solution in a population. The 
maximum rank of any solution cannot be more than N  (the population size). It is clear that 
the ranking procedure may not assign all possible ranks (between 1 and N ) to any population. 
For example, ranks 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18 are missing in the population 
used in the Figure 3.7 Detail on ranking can be found in Fonseca, et al., (1995). 
 
Fig. 3.7 Dominated and non-dominated solutions with rank values 
Once the ranking is performed, a raw fitness to a solution is assigned based on its rank. To 
perform this, first the ranks are sorted in ascending order of magnitude. Then a raw fitness is 
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assigned to each solution by using a linear (or any other) mapping function. Usually, the 
mapping function is chosen so as to assign fitness between N  (for the best-rank solution) and 
1 (for the worst-rank solution). Thereafter, solutions of each rank are considered one at a time 
and their raw fitnesses are averaged. This average fitness is then called the assigned fitness to 
each solution of the rank. In this way, the total allocated raw fitness and total assigned fitness 
to each rank remain identical. 
Moreover, the mapping and averaging procedure ensures that better ranked solutions have 
higher assigned fitnesses. In this way, non-dominated solutions are emphasised in a 
population. (Fonseca et al., 1993, Deb, 2001, Fonseca and Fleming, 1998). The rest of the 
algorithm is the same as that in a classical GA. Selection uses Baker’s stochastic universal 
sampling algorithm (Baker, 1987), which is optimal in terms of bias and spread. GA operators, 
namely crossover and mutation, are employed on the selected individuals to form the next 
generation (Goldberg, 1989). Selected parents are paired up and recombined with high 
probability (0.8). Mating restriction is implemented by forming pairs of individuals within a 
distance of each other in the objective space, where possible. Reduced-surrogate shuffle 
crossover (Booker, 1987) is used for recombination. The mutation rate for this optimisation 
process was set at 0.01%. The algorithm flowchart is presented in Figure 3. 8.  
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Fig. 3.8 Flowchart of MOGA optimisation 
There are various flavours of MOGA in circulation, varying in implementation of these 
parameters, but in essence the algorithms all follow a standard procedure, described below.  
Start with a randomly generated population of n l-bit strings, which initialise population. 
Maxgen, the number of gen will be compared with the limitation maxgen (if gen > maxgen) 
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that mean the processing will stop; if not will continue to evaluate the solutions or offer 
desired outputs. 
 Calculate the fitness f(x) of each string in the population.  
 Repeat the following steps until n new strings have been created:  
o Select a pair of parent strings from the current population, the probability of 
selection being an increasing function of fitness. Selection is done "with 
replacement" meaning that the same string can be selected more than once to 
become a parent.  
o With the crossover probability, cross over the pair at a randomly chosen point 
to form two new strings. If no crossover takes place, form two new strings that 
are exact copies of their respective parents.  
o Mutate the two new strings at each locus with the mutation probability, and 
place the resulting strings in the new population.  
3.8 Summary 
The most important challenge of cancer treatment is to maintain the normal physiological 
states of the patient’s body system during the course of different treatment schedules. This 
can be achieved by optimising chemotherapy treatment in such a way as to reduce tumour 
burden to a minimum level with minimum/acceptable toxic side effects. The other factors 
considered in chemotherapy include the stage of the disease, scheduling of the therapy and 
interaction of the drugs. The mathematical models are generally developed based on a set of 
differential equations. The purpose of using mathematical models for cancer chemotherapy is 
to predict and control the course of the disease when a treatment is scheduled.  
  CHAPTER 3 
 
73 
 
The multi-objective optimal chemotherapy control model aims to reduce the number of 
cancer cells after a number of fixed treatment cycles with minimum side effects. Close-loop 
control methods, namely I-PD and PID, are designed to control the drugs to be infused to the 
patient’s body. In the proposed method, several design objectives, constraints and associated 
goal values are defined prior to the optimisation process and a wide range of solutions have 
been obtained satisfying all design goals and trading-off between two main but conflicting 
objectives of chemotherapy treatment; reducing cancerous cells and reducing toxic side 
effects. It is interesting to note that the design approach can offer flexibility in decision 
making and suitable solutions can be picked under different trade-off conditions. Many 
solutions may be found out of this method, as will be discussed in subsequent Chapters, and 
used to reduce the number of cancerous cells to a very low level, not achieved so far. 
Moreover, the average toxicity level and drug doses during the treatment are also found to be 
low.  
One or more compartment models of cancer cells population have been considered as will in 
order to show the transition rates between proliferating and quiescent cells as non-specified 
functions of the total population. The understanding of the cell’s behaviours and division 
improves the treatment effectiveness. Some of the treatment models considered the cancer 
cells as one and many compartments, based on the mutations and behaviours of all cancer 
cells.  The big challenges are to balance the benefits and the side-effect of the chemotherapy 
cancer treatment. The proliferating cells at the tissue are considered as active cancer cell and 
need to be treated and divided to compartments called phase specific.  
The single drug model has been designed for one compartment as a basic and standard cancer 
chemotherapy drug scheduling. The multi-drug regimen models are designed as well to avoid 
the weakness of the some chemotherapy cancer drug treatment models. The cancer cells 
  CHAPTER 3 
 
74 
 
divided for example on four and eight compartments, based on the sensitivity of the cancer 
cell to the drug.   
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CHAPTER 4 
 
The Experiments and Results 
4.1. Non phase specific treatment 
The simplest mathematical models which are commonly used in research for optimal 
control of cancer chemotherapy consider entire cell cycle as one compartment (Martin, 1992, 
Swierniak, 1994). In many cases, these single compartment models prove to be inadequate 
and do not seem realistic due to the over simplified nature of the model compared to actual 
biological system. The actions of chemotherapy agents are based upon an understanding of 
the cell cycling mechanisms. In general, the cell cycle comprises of five stages which should 
passes thorough dependents of the type of the cell as shown in Figure 2.2 in Chapter 2.  
Matlab Simulink toolbox provides an interactive, graphical environment for modelling. The 
whole simulation is carried out in the Simulink environment with some m-files of Matlab
 
(The Mathworks, Inc., 2010).  The simulink model is chosen because it allows simple 
construction of control system with simple built-in components. Differential equations 
associated with relevant parameters were implemented in Simulink to develop a 
mathematical model of body metabolism, cell functions and their response to chemotherapy 
treatment to predict the number of tumour cells and to optimise the control parameters. 
An automated close-loop control method is also developed to design the drug doses during 
the whole treatment period. Figure 4.2 shows the proposed chemotherapy drug scheduling 
scheme where drug concentration of the patient model is used as the feedback signal in order 
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to maintain a predefined level of drug concentration at the tumour site. In this investigation, a 
feedback control system was used including a Proportional-Integral-Derivative (PID) 
(Astrom, et el, 1993) and a variant of it (different structures of PID), namely Proportional- 
Integral-Derivative (PID) were designed to control the drugs to be infused to the patient’s 
body. The proposed controllers; both PID and I-PD, involve three parameters: the 
proportional gain   , integral gain   , and derivative gain   . One of the outputs of the model 
      including the drug concentration is compared with a predefined reference level      and 
an error signal      is generated by the difference between the reference input and drug 
concentration as follows: 
                                                          (4.1) 
The error signal is used to generate the output of PID controller,      as: 
      [          ∫          
 
  
 
 
     ]                                                         (4.2) 
Here, the first term of equation (4.2) gives a system control input (drug doses) proportional 
with the error     , the second term (integral) gives an addition from the sum of the previous 
errors and last term gives an addition from the rate of change in the error to the system 
control input (drug doses). 
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Fig. 4.1 Schematic diagram of proposed Control Scheme 
In order to evaluate the effectiveness of MOGA in chemotherapy drug scheduling, several 
representative solutions are further assessed. To validate all solution sets, three solutions are 
selected on each Pareto front, one from each region. The solutions are selected in such a way 
that two fall on either extremes points of the two objectives, the other is at approximately in 
the middle of objective domain. Three selected solutions for PID with Rep & Cont (Repeated 
and Continuous), as shown in Figure 4.3(a) are denoted as PID-1, PID-2 and PID-3, for I-PD 
with Rep & Cont, see Figure 4.4(a) are denoted as I-PD-1 and I-PD-3 for the drug doses. 
Similarly three solutions are selected from each Pareto fonts of Figure 4. 3(b) where Rep is 
used as reference input with I-PD and PID controllers. These solutions are indicated as: PID-
4, PID-5, PID-6, I-PD-4, I-PD-5 and I-PD-6 respectively.  
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Fig. 4.2(a) Pareto optimal solution sets with Rep & Cont for PID and I-PD controllers 
 
 
Fig. 4.2 (b) Pareto optimal solution sets with Rep for PID and I-PD controllers 
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4.1.1. Results   
To obtain different performances, three decision variables,   ,    and    
corresponding to each aforementioned solution were fed to the I-PD and PID controllers and 
the whole system along with the patient model is simulated for 84 days. Then the output of 
the controller,     , which is the desired chemotherapy drug scheduling and all outputs of the 
patient model, such as, drug concentration at the tumour site, toxicity and reduction in 
cancerous cells were recorded. For all solutions, average and maximum values of drug doses, 
drug concentration and toxicity during the whole period of treatment and number of remaining 
cells at the end of the treatment are shown in Table 4.1, where the minimum values considered 
as zero. It is important to note that, the selected solutions cover all solutions in the objective 
domain generated by MOGA optimisation process.  
Table 4. 1 Performances of selected solutions 
Controller 
type 
Ref. Input 
to 
the 
controller 
Selected 
Solutions 
Drug 
Doses 
Drug 
Concentration 
Toxicity Reduction of cancerous 
cells 
(at the end of 84 days) 
Max Avg Max Avg Max Avg Cancer 
Cells 
remaining 
% 
reduction 
IPD 
Rep & Cont 
IPD-1 18.5 11.7 50 32.3 98.7 55.7 15 ≈ 100% 
IPD-2 14.6 8 39.5 21.8 98.7 43.5 145 ≈ 100% 
IPD-3 14.6 7.2 39.4 19.6 98.6 41.3 798 ≈ 100% 
Repeated 
IPD-4 18.4 9.4 49.6 25.4 67 58.5 2.5x10
5
 > 99% 
IPD-5 11.8 8.9 32 24 66.4 55.3 3.3x10
5
 > 99% 
IPD-6 10.7 8.4 28.8 22.8 66.4 52.7 4.2x10
5
 > 99% 
PID 
Rep & Cont 
PID-1 18.5 12.8 50 34.5 98.8 80.5 16 ≈ 100% 
PID-2 14.6 11.7 39.5 31.6 98.8 76 193 ≈ 100% 
PID-3 14.6 11.3 39.5 30.6 98.7 70 526 ≈ 100% 
Repeated 
PID-4 15.7 8.7 42.3 23.5 70 57 2.5x10
5
 > 99% 
PID-5 12.6 8.4 34 22.6 63.3 53.2 2.9x105 > 99% 
PID-6 11.3 8 30.7 21.5 62.9 51.2 3.8x105 > 99% 
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4.1.1.1 Drug Scheduling 
The reference input to the controller,      is the desired drug concentration to be maintained 
at the tumour site while delivering drugs into patient’s body. The reference input should be 
chosen in such a way that the drug concentration should remain within the limit as indicated 
by equation (3.5) in Chapter 3. This will not only enable the chemotherapy drugs kill 
cancerous cells but also limit the toxic side effects. Two types of reference inputs are 
designed and tested with both PID and IPD controllers in this work and these are: (i) 
Repeated and Continuous and (ii) Repeated. For ease of discussions, these two reference 
inputs will be indicated as Rep&Cont and Rep throughout the paper. The design of reference 
inputs is motivated by clinical evidences and some state of the art works in this field (Liang 
et al., 2008).  
In case of Rep&Cont, the desired drug concentration is set to a maximum value of 50 for 
the first two days. This implies higher drug doses at the beginning of the treatment which has 
strong relevance in clinical practice (Liang et al., 2008). To avoid risks of toxic side effects, 
the desired reference level is reduced by 10% for the next couple of days and then reduced to 
almost zero next two days. For the remaining period of the treatment, the reference for drug 
concentration is set at 40 which is 20% less than the initial value. For clarity, Figure 4.3(a) 
shows the reference input Rep&Cont for the first two weeks. It is mentioned that the 
treatment is design for 12 weeks (84 days) as suggested by many researchers (Martin and 
Teo., 1994, Liang et al., 2008). The fixed level of reference from day 6 to the end implies 
stable drug concentration as well as drug doses for that period.  
For reference input Rep, the desired drug concentration is set to maximum allowable value 
of 50 for one day followed by a minimum value of zero for next day and this pattern repeats 
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for 84 days of treatment. The close-loop control method results high doses with high 
reference and low doses with low reference level. The low reference level for alternate days 
may be attributed to rest days as observed in clinical doses. More importantly this will help 
reduce the toxic side effects during the treatment. Figure 4.3(b) shows the reference input 
Rep for the first two weeks, for clarity, and it repeats similar pattern for the remaining days of 
treatment. 
The efficacy of the drug doses depends on three parameters         and   of PID and I-
PD controllers. In this work, Rep&Cont and Rep are used as the reference inputs to the close-
loop control system. For Rep&Cont as reference input with a specific value, as mentioned 
above will ensure approximately a constant level of drug concentration for most of the time 
of the treatment cycle. With reference input, Rep, although the drug concentration will 
fluctuate, it will remain below the maximum allowable value.  
 
Fig. 4.3 (a) Reference input: Rep&Cont 
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Fig. 4.3 (b) Reference input: Rep 
Maximum drug doses during the whole period of treatment vary in the range of 10-19 
while average of it remain within 8-13 for I-PD and PID, respectively. Figure 4.4(a) shows the 
chemotherapy drug scheduling for solutions; I-PD-1, I-PD-3, PID-1 and PID-3. For  clarity, 
solutions lying on extreme ends of Pareto fonts are selected and responses of other solutions 
will remain within the limits of these solutions.  
It is noted that, above four solutions use Rep & Cont as the reference input. For 
solutions I-PD-1 and PID-1, the drug doses sharply rise to a maximum value of 18.5 in first 
two days of treatment and then slightly reduce on days 3 and 4 followed by a sharp decrease 
on days 5 and 6. The drug doses then rise sharply to a level of nearly 14.5 and remain almost 
stable till the end of the treatment following the input reference (input dosage). The drug 
doses, for solutions, I-PD-3 and PID-3, rise slowly and steadily in first few weeks and then 
reach almost the same stable level in 8 weeks time. Figure 4.4(b) shows the chemotherapy 
drug scheduling for solutions; I-PD-4 and PID-4 where the reference input is Rep. In both 
cases, the drug doses increase sharply in first two days and then fluctuate within a range of 6-
12 for the whole period of treatment to balance between the input and the feedback which 
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increase the effectiveness of the treatment. It is important to note that the drug doses are 
relatively lower for all solutions.  
 
 
Fig. 4.4 (a), Drug doses throughout the whole period of treatment 
 
Fig. 4.4 (b) Drug doses throughout the whole period of treatment 
0 10 20 30 40 50 60 70 80
0
5
10
15
20
Time (days)
D
ru
g
 d
o
s
e
s
 
 
I-PD-1
I-PD-3
PID-1
PID-3
0 10 20 30 40 50 60 70 80
0
5
10
15
20
time (days)
d
ru
g
 d
o
s
e
s
 
 
I-PD-4
PID-4
  CHAPTER 4 
 
84 
 
4.1.1.2 Drug Concentration 
The cancer drugs were infused to the patient body during the whole period of the 
treatment cycle. The drug flow with the blood stream depends of the metabolism of the 
patient body.  Drug concentrations in the blood can be determined and a plotted against time. 
In most instances, the time course of a drug’s concentration in the plasma correlates well with 
the onset, intensity, and duration of the pharmacologic effect (Laurence, et al., 2005). Thus, 
the measurement of sequential plasma concentration of drugs after their administration is 
used to establish dosage regimens that are likely to produce the desired therapeutic levels for 
appropriate periods of time, without the risk of drug failure or toxicity. Toxic drug levels may 
be observed when the body's normal mechanisms for metabolising and excreting drugs are 
impaired, as commonly occurs in patients with liver or kidney disorders and in infants with 
immature organs (P. Blackall, 2010).  
In this work, the chemotherapy drug scheduling is obtained with PID and I-PD controllers 
and MOGA optimisation process throughout the whole period of treatment cycle. More 
importantly, the drug doses are much lower compared to conventional doses during 84 days 
of treatment. It is important to note that, the optimal doses of chemotherapy drugs are in 
general, and lower doses of these drugs can reduce the toxic side effects during the treatment 
cycle and thereby improve the quality of life of the cancer patient. Figure 4.5(a) shows the 
drug concentration against desired/reference input for solutions; I-PD-1, I-PD-3, PID-1 and 
PID-3 at the tumour site due to chemotherapy drug scheduling obtained for those cases. It is 
interesting to note that, the drug concentration increases and decreases with time in a similar 
manner as observed in case of drug scheduling. Figure 4.5(b) shows the drug concentration for 
solutions; I-PD-4 and PID-4 where the reference input is Rep and it also follows the 
corresponding drug scheduling as observed in Figure 4.5(b). It is important to note that, drug 
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concentrations for all solutions remain within the limits set by condition and average values 
are below 35 which are significantly lower compared to maximum allowable value 50. 
 
Fig. 4.5(a), Drug concentration throughout the whole period of treatment 
 
Fig. 4.5(b), Drug concentration throughout the whole period of treatment 
4.1.1.3 Toxicity   
The maximum and average toxicity of all selected solutions are determined during the 
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toxicity for all solutions are always lower than the maximum allowable value as mentioned in 
the conditions and average toxicity levels are far lower than this. The toxicities, for I-PD-1, I-
PD-3, PID-1 and PID-3, developed due to the corresponding chemotherapy drug scheduling 
are shown in Figure 4.6(a).  For I-PD-1 and PID-1, the toxicity sharply rises in first two days 
because of high drug doses infused to the patient. The toxicity then reduces and finally gets 
stable for the whole period at approximately a level of 98. For solutions I-PD-3 and PID-3, 
the toxicity gradually increases and becomes stable at nearly same value in 8/9 weeks time. 
Figure 4.6(b) shows the level of toxicity for solutions I-PD-4 and PID-4 where reference 
input is Rep. The toxicity sharply increases to a level of 60 in first week of treatment and then 
fluctuates between ranges of 58-68 for the remaining period. It is important to note that, 
toxicities in all cases remain under control and lower than the maximum limiting value set in 
design objective and constraint of the optimisation process.  
 
Fig. 4.6(a), Toxicity throughout the whole period of treatment 
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Fig. 4.6(b), Toxicity throughout the whole period of treatment 
4.1.1.4 Reduction of cancerous cells 
A reduction of the cancerous cell is considered as the main aim of chemotherapy 
treatment. Before the treatment starts, the number of proliferation cells is set at 1x10
9
, as used 
by many researchers (Martin and Teo, 1994, Liang et al, 2008) and the reduction of 
cancerous cells for all solutions are more than 99% with some approaching to 100%. The 
maximum cell reduction is obtained with a drug scheduling corresponds to solution I-PD-1, 
followed by PID-1 and I-PD-2. The number of remaining cells is much lower with reference 
(Rep & Cont) while this number is in the range of 10
5
 with reference input Rep for both PID 
and I-PD controllers. 
 Figure 4.7(a) shows the reduction of cancerous cells during the whole period of treatment for 
solutions I-PD-1, I-PD-3, PID-1 and PID-4. For solutions I-PD-1and PID-1, at the first three 
days of the treatment the cancer cells look continuing growing until the drug dosages take 
place at the patient body, after that when drug becomes effective the rate of cell reduction is 
very high then further reduced remarkably in 3 weeks time. The numbers of cancer cells 
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remaining at the end of treatment for I-PD-1 and PID-1 were are 15 and 16 respectively. For 
solutions, I-PD-3 and PID-3, the rate of reduction was rather slow at the beginning but 
significant after 6 weeks. Figure 4.7(b) shows the reduction of cancerous cells for solutions I-
PD-4 and PID-4. In both cases the rate of reduction is steady and reduces to a significant 
level within 6 weeks of the treatment. 
 
Fig. 4.7(a),Cells reduction throughout the whole period of treatment 
 
 
 
Fig. 4.7(b) Cells reduction throughout the whole period of treatment 
0 10 20 30 40 50 60 70 80
0
2
4
6
8
10
12
x 10
9
time (days)
N
u
m
b
e
r 
o
f 
c
e
lls
 
 
I-PD-1
i-PD-3
PID-1
PID-4
0 10 20 30 40 50 60 70 80
0
2
4
6
8
10
12
x 10
9
time (days)
N
u
m
b
e
r 
o
f 
c
e
lls
 
 
I-PD-4
PID-4
  CHAPTER 4 
 
89 
 
4.2 Specific Cancer cells treatment 
As mentioned earlier, the main aim of chemotherapy treatment is to 
eradicate/minimise the cancer cells at the tumour site with minimum toxic side effects 
produced by the drug throughout the whole period of the treatment. Very often, cancer cells 
grow resistance to a drug if it continues for a long time and resistance to drug causes failure 
to treatment in most cases. The combinations of multiple drugs can decrease the drug 
resistance (Martin and Teo, 1994). Toxic side effects developed due to the infusion of 
chemotherapy drugs always pose a major challenge in drug scheduling. So drug doses and 
their cycles of intervals must be designed in such a way as to make the treatment effective, 
i.e., eradicate the tumour with minimum/tolerable toxic side effects.  
The actions of the cancer chemotherapy drugs are based upon an understanding of the cell 
cycling mechanisms in order to make the course of the treatment more effective. A number of 
models have been developed to study and analyse the effects of drugs on cancer cells by 
dividing the tumour into number of sub-populations (Tes, et, al, 2007, Martin and Teo, 1994, 
Panetta and Adam, 1995). In 1994, Martin   introduced a model for two non-cross resistant 
agents who considered interaction between drug concentrations during the treatment within 
the patient body and the cells. A model has been developed for cancer chemotherapy drug 
scheduling to improve the performance throughout whole period of the treatment based on 
drug scheduling.  
A schematic diagram of chemotherapy drug scheduling scheme for cancer treatment is shown 
in   Figure 4.8. A feedback control method was developed in order to maintain a predefined 
level of drug concentration at tumour sites. A variant PID control, namely I-PD was used to 
control the drug to be infused to the patient’s body. The proposed I-PD controller was used to 
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control the drug to be infused to the patient’s body involving three parameters, the 
proportional gain   , integral gain   , and derivative gain   , Drug concentration at the 
tumour is used as the feedback signal to the controller which is compared with a predefined 
reference level. The difference between reference input and drug concentration at tumour site, 
output-     , of the model is called the error which was used as input to the controller. The 
integral value gives an addition from the sum of the previous errors to the system input (drug 
doses).  
 
Fig. 4.8 Schematic diagram of the proposed drug scheduling scheme 
 In the control model, the ‘Proportional’ value gives a system control input (drug doses) 
proportional to the feedback signal       and ‘Derivative’ value gives an addition from the 
rate of change in the      to the system control input (drug doses). The output of the 
controller      as: 
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In order to evaluate the effectiveness of MOGA in chemotherapy drug scheduling, several 
representative solutions were further assessed. To validate the solution set, three solutions 
were selected on the Pareto front, one from each region. The solutions were selected in such a 
way that two fall on either extremes points of the two objectives, the other is at approximately 
in the middle of objective domain. Three selected solutions, as shown in Figure 4.9 which 
denoted as Case-1, Case-2 and Case-3 for further discussion. As mentioned earlier, an I-PD 
controller was developed to design the chemotherapy drug doses for cell cycle specific cancer 
treatment. The close-loop controller was designed in such a way that drug concentration, one 
of the outputs of the patient model can be maintained to the tolerable level which set by 
predefined level of the reference input to the controller.  
 
Fig.4.9 Shows three selected solutions, Case-1, Case-2 and Case-3 
4.2.1. Results 
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after few weeks the difference becomes very small and then reduces to nearly zero. To make 
the chemotherapy drugs effective, the drug concentration at the tumour site should be 
maintained at a desired level for the whole period of treatment and this was implemented by 
using a fixed level of signal, called step input. In this work, the reference to the controller 
(desired drug concentration) was selected by the MOGA optimisation process and for 
different solutions the reference levels are different. For example, the reference levels for 
Case-1, Case-2 and Case-3 are 12.08, 12.17 and 11.66 respectively.    
To obtain different performance measures in relation to chemotherapy treatment, three 
decision variables,   ,    ,    and reference input (desired drug concentration) corresponding 
to solution, Case-1, are feed to the I-PD controller and the feedback control system and the 
whole system along with the patient model was simulated for 84 days. Then the output of the 
I-PD controller,    , which is the desired chemotherapy drug scheduling for Case-1, was 
recorded. Several outputs of the patient model, such as, drug concentration at tumour site, 
toxicity, reduction of proliferating and quiescent cells and changes in normal cells were 
recorded due to the infusion of the designed chemotherapy doses. Similar procedure was 
repeated for Case-2 and Case-3 and similar parameters are recorded for the whole period of 
chemotherapy treatment. 
Figure 4.10(a) shows the chemotherapy drug scheduling for Case-1, Case-2 and Case-3. The 
response of the patient model due to the infusion of these drug scheduling are shown in 
Figures 4.10(b) and (f). It is noted that, the response of the patient model are expressed in 
terms of several parameters such as, drug concentration, toxic side effects, reduction of 
proliferating and quiescent cells and changes in normal cells during the whole period of 
treatment. Moreover, the maximum and average levels of drug doses, toxicity and drug 
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concentrations for all three cases are calculated and presented in Table 4.2, where is the 
minimum value considered zero. Furthermore, percentage of reductions in proliferating and 
quiescent cells at the end of chemotherapy treatment were calculated and showed in Table 4.2 
As mentioned earlier, in chemotherapy drug scheduling problem, number of normal cell 
population is often considered as an indication of toxic side effects developed in the patient’s 
body. Since the normal cells are adversely affected by the chemotherapy drugs, the level of 
toxicity is assumed to be inversely proportional to the number of normal cells. Moreover, the 
number of normal cells remaining at the end of treatment is giving an indication about the 
physiological state of the patient. So this number was also calculated and displayed in Table 
4.2. 
Table 4.2: Performances of drug scheduling techniques  
Example 
solutions 
Value 
of  
Ref. 
input  
For the whole period of treatment At the end of 84 days treatment 
 Drug doses Drug 
concentration 
Toxicity Reduction of 
Proliferating 
Cells 
Reduction of 
Quiescent 
cells 
No. of 
Normal cells 
Max Avg Max Avg Max Avg 
Case-1 12.08 4.5 3.4 12 9.2 34.5 27.7 72.2% 60.4% 1.0002x10
8
 
Case-2 12.17 4.5 3 12 8.3 33.4 23.4 71.2% 58.9% 1.0024x10
8
 
Case-3 11.66 4.5 2.8 11.7 7.5 31.9 21.2 68.1% 55.1% 1.2815x10
8
 
4.2.1.1 Drug Scheduling 
Figure 4.10 (a) shows the chemotherapy drug scheduling for Case-1, Case-2 and 
Case-3. In all cases, the drug doses increase from zero and finally become stable at a certain 
value. It is noted that the rate of increase is different for different cases. For Case-1, the doses 
reach maximum value of 4.5 within the first week of treatment and for the remaining periods 
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it becomes stable at that value. For Case-2, the chemotherapy drug scheduling takes slightly 
more than two weeks to reach the maximum and stable level of 4.5 whereas for Case-3, it 
takes nearly seven weeks to reach the fixed and stable level of 4.3. Although in all three cases 
the maximum chemotherapy drug doses are nearly same but the average levels of drug doses 
over the whole period of treatment are different. For Case-1, the average drug dose is 
maximum, which is 3.4 whereas this value is minimum (=2.8) for Case-3. For Case-2, the 
average drug dose is moderate (=3) relative to other two cases. 
In this work, the chemotherapy drug scheduling obtained with I-PD controller and MOGA 
optimisation process was continuous throughout the whole period of treatment. More 
importantly, the drug doses were much lower compared to conventional doses during 84 days 
of treatment. It is important to note that, phase specific chemotherapy drugs, such as Vinca 
alkaloids, Hydroxyurea, Cytosine arabinoside, Methotrexate, 6-Mercaptopurin, 6-
Thioguanine, Procarbazin, VM-26 and VP16-213 (Liang et al., 2008) are, in general, toxic 
agents and lower doses of these drugs can reduce the toxic side effects during the treatment 
cycle and thereby improve the quality of life of the patient.  
 
Fig. 4.10(a) Chemotherapy drug doses for whole period of treatment 
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4.2.1.2 Drug Concentration 
Figure 4.10(b) shows the drug concentration against desired/reference input for Case-
1, Case-2 and Case-3 at the tumour site due to chemotherapy drug scheduling obtained for 
those cases earlier in Figure 4.10(a). It is interesting to note that, the drug concentrations, for 
all three cases, increase gradually in similar manner as  observed in case of corresponding 
drug scheduling and follow corresponding reference levels/desired levels. The drug 
concentrations at tumour site reach a maximum value as set by the corresponding 
reference/desired values.  
It is also noted that, like average drug doses, the average drug concentrations also vary from 
case to case; Case-1 having maximum average value of 9.2 followed by Case-2 and Case-3, as 
listed in Table 4.2. More importantly, it is noted that, the average and maximum drug 
concentrations are always much lower than the allowable maximum value indicated in design 
objective and constraint for this particular parameter.  
 
Fig. 4.10(b) drug concentration for whole period of treatment 
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4.2.1.3 Toxicity   
The toxicities, for Case-1, Case-2 and Case-3, developed due to the corresponding 
chemotherapy drug scheduling are shown in Figure 4.10(c).  For all three cases, the toxicities 
gradually increase from the first day of treatment and finally settle to a steady value after few 
weeks in a similar manner as observed in case of drug scheduling and drug concentration. The 
maximum level of toxicity is observed with the drug scheduling obtained with Case-1 and the 
value is 34.5 whereas the minimum toxicity is caused by Case-3. 
The average toxicities for Case-1, Case-2 and Case-3 are 27.7, 23.4 and 21.2, respectively. 
Like maximum toxicity, the average toxicity is also maximum with Case-1, followed by Case-
2 and Case-3. It is important to note that, toxicities in all cases remain under control and much 
lower than the maximum limiting value set in design objective and constraint of the 
optimisation process. 
 
Fig. 4.10(c) Toxicity for whole period of treatment 
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4.2.1.4 Reduction of proliferating cells 
The reduction of proliferating cells is the main target of chemotherapy treatment for cancer 
tumour. Before the treatment starts, the number of proliferation cells was set at 2x10
11
, as used 
by many researchers in cell cycle specific cancer treatment (Dua et al., 2008). Figure 4.10(d) 
shows the reduction of proliferating cells during the whole period of treatment. For Case-1, 
Case-2 and Case-3, the percentage of reductions obtained using the drugs scheduling shown in 
Figure 4. 10(a) is 72.2%, 71.2% and 68.1% respectively.  
 
Fig. 4.10(d) Reduction of proliferation cell for whole period of treatment 
4.2.1.5 Reduction of quiescent cells 
Quiescent cells were also be reduced in cancer treatment as indicated in the design 
objectives. At the beginning the chemotherapy treatment, the total number of quiescent cell is 
assumed as 8x10
11
 (see Table 3. 1). During the treatment period, the number gradually 
decreases depending on chemotherapy drug doses and this is shown for all three cases in 
Figure 4.10(e). It is important to note 60.4%, 58.9% and 55.1% respectively. 
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Fig. 4.10(e) Reduction of quiescent cell for whole period of treatment 
4.2.1.6 Changes in normal cells 
The chemotherapy drugs adversely affect the normal cells during the treatment. In the 
patient model used in this work, the number of normal cells was assumed 10x10
8
 before the 
administering the chemotherapy drugs into patient’s body. Figure 4.10(f) shows the changes of 
normal cells during the whole period of treatment for all cases. For Case-1, Case-2 and Case-
3, the number of normal cells remaining at the end of 84 days treatment are 1.03x10
8
, 
1.0024x10
8
 and 1.2815x10
8
 respectively. It is important to note that, in all cases the number of 
remaining normal cells are more than the threshold value, 1x10
8
, as indicated in condition and 
in design constraint earlier. It is mentioned that these higher values of remaining normal cells 
are attributed to lower toxic side effects and better physiological conditions of patients.  
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Fig.4.10(f) Number of the normal cells for whole period of treatment 
4.3. Four Compartments Model 
This section focuses on multi-drug chemotherapy scheduling where two drugs are 
used and, for ease of discussion, these drugs are indicated by A and B, respectively. To assess 
the effectiveness of two drugs in chemotherapy treatment, a tumour model consists of four 
compartments is considered. A schematic diagram of multi-drug scheduling scheme for 
chemotherapy treatment is shown in   Figure 4.11. A feedback control method I-PD was 
developed to control the drug to be infused to the patient’s body. The overall control structure 
contains two I-PDs controllers; one for drug A and another for drug B.  Each I-PD controller 
involves three parameters, the proportional gains    integral gain    and derivative gains   . 
Drug concentration at the tumour is used as the feedback signal to the controller which is 
compared with a predefined references level. The difference between each two is called the 
error which is used as input to the controller. The output of the controller for drug A       is 
formed as: 
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          ∫        [   
 
  
 
 
               ]                                                                     
While the output of the controller for drug B       is:  
           ∫        [   
 
  
 
 
               ]                                                                
where,                 are the errors which are the differences between references 
𝑋       𝑋   and drugs concentrations                . These are expressed as: 
      (         )                                                                                                                          
      (𝑋        )                                                                                                                          
It is noted that  𝑋       𝑋    indicate the reference signals to the controllers which can be 
depicted as the desired drugs concentrations to be maintained at the tumour site during the 
whole period of the treatment. It is the noted that when                 are zero, the drugs 
concentrations at tumour site will be equal to the desired drug concentrations. In such case, the 
cell killing will be maximum. If the differences between 𝑋   and       and 𝑋   and    are 
positive large or not stabile then the drugs concentrations will be lower than the desired level 
and in such case, the cell killing will be much lower than expected. It is required to tune the 
six parameters                         and     of I-PDs controllers to achieve the desired 
performance. In this work, MOGA is used to optimise these parameters of the I-PDs 
controllers and references to the controller. It is important to note that the whole control 
scheme and drugs scheduling is designed for a period of 84 days as recommended by many 
researchers (Tes, et al, 2007, Martin and Teo, 1994 and Ochoa and Burke, 2007). 
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Fig. 4.11 Schematic diagram of the proposed multi-drug control scheme 
The whole simulation was carried out in the Simulink environment with some .m-files of 
Matlab
®
 (The Mathworks, Inc., 2010). The MOGA optimisation process started with a 
randomly generated population called chromosomes. A standard population size of 50 was 
chosen in this work. An initial population of dimension 50×8×12 was created where number 
of individuals and parameters in each individual were 50 and 8 respectively. Each parameter 
was encoded as 12 bit Gray code which is logarithmically mapped (Chipperfield et al, 1994) 
into real number within a range of [0, 2] for first six parameters and a range of [10, 50] for the 
remaining parameters. Each individual represents a solution where the first six elements were 
assigned to controller’s parameters;                     ,              respectively as indicated 
in the conditions. The seventh and eighth elements of each individual were assigned to the 
reference inputs, 𝑋        𝑋   to the close-loop control system.  
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The MOGA optimisation process was run for 200 generations in order to minimise the 
objectives simultaneously. It is worth mentioning that through the trial and error, 200 
generations are found as the minimum number of generation to obtain highest level of 
convergence. Solutions not satisfying aforementioned design constraints are penalised with 
very high values, called penalty function. This penalty function will reduce the probability of 
solutions yielding unacceptable values along any design objectives dominate the optimisation 
process. On the other hand, favourable acceptable solutions to be selected for reproduction 
that in turn may generate better solutions in subsequent generations. In MOGA optimisation 
process, non-dominated solutions called Pareto optimal set and the corresponding decision 
variables were updated and preserved at the end of each generation. As the algorithm 
proceeds the number of preserved non-dominated solutions increases and more importantly, 
the solutions gradually get better and tend to move towards x-axis and origin of y-axis in the 
objective domain. A wide range of non-dominated solution satisfying all design constraints, 
objectives and associated goal values as were obtained at the end of maximum generation.  
For a three-objective minimisation problem, a parallel line representation is shown in Figure 
4.12 where x-axis is marked by three equidistant points representing design objectives to be 
minimised and y-axes at those points represent the values of corresponding objective 
functions.  Moreover, three objective functions for each solution are connected by a line of 
specific style and colour. For clarity and ease of discussion, only few non-dominated 
solutions yielding value for objective-2 less than150 are shown in Figure 4.12. In such a case, 
individuals (solutions) that fall close to x-axis are better than those away from x-axis. 
Moreover, crossing-lines for two consecutive objectives indicate conflict between them 
whereas non-crossing lines indicate that objectives are not in conflict. It is observed that a 
solution giving minimum value along one objective yields relatively higher values along 
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other two objective domains. Similar nature is observed with other solutions. Although no 
solution can minimise all three design objective simultaneously to lowest possible values 
because of inherent conflict, each solution has equal potential as per as trade-off among 
different objectives are concerned.  
 
Fig. 4.12 Non-dominated solutions of MOGA optimisation at generation-200 
4.3.1 Results 
In order to evaluate the effectiveness of the proposed control strategy and MOGA 
optimisation process, an example solution yielding a minimum value for objective 2 is 
analysed in detail. To obtain different performance measures in relation to chemotherapy 
treatment, eight decision variables; 6 controller parameters (    ,     ,    , ,    ,     and 
   ) and 2 reference inputs (𝑋        𝑋   ) were fed to the feedback control system and the 
whole system along with the patient model is simulated for 84 days. Then the outputs of two I-
PD controllers,        and       are drug scheduling for drugs A and B were recorded. 
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Several outputs of the patient model, such as, drug concentration at tumour site, toxicity and 
reduction of cancer cells are recorded due to the infusion of the designed chemotherapy doses.  
Figure 4.13(a) shows the chemotherapy drug scheduling for drug (A and B). In both drugs, the 
drug doses increase from zero and finally become stable at a certain value. It is noted that the 
level of increase is different for two drugs. It is worth to mention that the dosage of the multi-
drug is lower as compared with single drug. Moreover the effectiveness of multi-drug by 
reducing the resistance of the chemotherapy cancer treatment increases the performance of the 
treatment. For drug A, the doses reach maximum value of 13.12 within the first week of 
treatment and for the remaining periods it becomes stable at that same value. For drug B, the 
drug dosage takes slightly more than one week to be to reach the maximum and Stable for rest 
of the period at 12.91.  
 
Fig. 4.13 (a) Chemotherapy drug doses for drugs A and B 
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4.3.2.1 Drug concentration 
Figure 4.13(b) shows the drug concentration against desired/reference inputs for drug A 
and drug B at the tumour site due to chemotherapy drug scheduling obtained for both cases 
earlier in Figure 4.13(a). It is interesting to note that, the drug concentrations, for both drugs, 
increase gradually in similar manner as  observed in case of corresponding drug scheduling 
and follow corresponding references levels/desired levels. The drug concentrations at tumour 
site reach a maximum value as set by the corresponding references/desired values. More 
importantly, it is noted that, the maximum drug concentrations are always much lower than the 
allowable maximum value indicated in design objective and constraint for this particular 
parameter. The toxicities, for drug A and drug B, developed due to the corresponding 
chemotherapy drug scheduling are shown in Figure 4.13(a).   
 
Fig. 4.13(b) Drug concentrating for drugs A and B for both throughout the treatment period 
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4.3.2.2 Toxicity 
For both drugs, the toxicities gradually increase from the first day of treatment and finally 
settle to a steady value after few days in a similar manner as observed in case of drug 
scheduling and drug concentration as Figure 4.13(c) illustrated. It is noted that the level of 
toxicity for a multi-drug chemotherapy treatment is low compared with the single drug 
(Martin and Teo, 1994). The maximum level of toxicity is observed with the drug scheduling 
obtained with drug A and the value is 97.5 whereas the toxicity caused by drug B is at lower 
level of toxicity in comparison to drug A. The average toxicities for drug A and drug B are 
81.7 and 77.5 respectively. It is important to note that, toxicities in all cases remain under 
control and much lower than the maximum limiting value set in design objective and 
constraint of the optimisation process. The main aim of chemotherapy treatment to eradicate 
or minimise the cancer resistance cells to the minimum level after a number of fixed treatment 
cycles. Before the treatment starts, the number of cancer cells was assumed 4.60517×10
11
, as 
used by many researchers in cell cycle specific cancer treatment (Tes et al, 2007).  
 
Fig. 4.13 (c) Toxicity for drugs A and B for both throughout the treatment period 
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4.3.2.3 Cell reduction 
Figure 4.13(b) shows the effect of both drugs at the tumour site during the whole period of 
treatment. Figure 4.13(b) shows approximately 100% reduction of cancer cells during the 
whole period of treatment scheduling shown in Figure 4.13(a). 
 
Fig. 4.13(d) The cell reduction for both throughout the treatment period 
4.4  Proposed Control Scheme for Eight Compartments 
A schematic diagram of multi-drug scheduling scheme for three chemotherapy 
treatment is shown in Figure 4.14.  Feedback control methods using three I-PDs were 
developed to control the drugs to be infused to the patient’s body. The overall control 
structure contains three I-PD controllers - one for each drug. Each I-PD controller involves 
three parameters, the proportional gains    , integral gain    and derivative gains   . Drug 
concentration at the tumour is used as the feedback signal to the controller which is compared 
with a predefined reference level. The difference between each two is called the error which 
is used as input to the controller. It is noteworthy that  𝑋  , 𝑋   and 𝑋   indicate reference 
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signals to the controllers which can be depicted as the desired drug concentrations to be 
maintained at the tumour site during the whole period of treatment. To achieve the desired 
performance, nine parameters of I-PDs such as                                          
need to be tuned. In this research, MOGA is used to find suitable parameters for I-PD 
controllers and reference inputs (desired drug concentrations). 
The mathematical model containing eight compartments stating the effects of three 
drugs as explained earlier is implemented in Matlab/Simulink (The Mathworks, Inc., 2010) 
environment with parameters and values as illustrated in Table 4.3 (Tes et al, 2007). 
Moreover, the I-PD feedback control scheme was also developed in Matlab/Simulink 
environment. The MOGA optimisation process begins with a randomly generated population 
called chromosome. An initial population of dimension 50X12X12 was created where 
number of individuals and parameters in each individual are 50 and 12 respectively. Each 
parameter was encoded as a 12 bit Gray code which is logarithmically mapped (Chipperfield, 
et al, 2007) into real number within the range of [0,2] for first nine parameters and a range of 
(10,50) for the last three parameters. Each individual represents a solution where the first nine 
elements are assigned to the controller parameters. The last three elements of each individual 
are assigned to the reference inputs to the close-loop control system. The whole control 
scheme and drug scheduling are designed for a period of 84 days as recommended by many 
researchers (Tes et al, 2007, Martine and Teo, 1994 and Ochoa and Burke, 2007).  
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Fig. 4.14 Schematic diagram of the proposed multi-drug scheduling scheme 
 The MOGA optimisation process was run for 200 generations in order to minimise the all 
objectives simultaneously. It is worth mentioning that through trial and error, 200 generation 
was found as the minimum number of generation to obtain highest level of convergence. As 
the algorithm proceeds, number of preserved non-dominated solutions increases and more 
importantly, the solutions gradually get better and tend to move towards x-axis and origin of 
y-axis in the objective domain. A wide range of non-dominated solution satisfying all design 
constraints, objectives and associated goal values as were obtained at the end of maximum 
generation. A similar method has been followed for solutions not satisfying as mentioned 
above for three objectives. For a four-objective minimisation problem, a parallel line 
representation is shown in Figure 4.15 where x-axis is marked by four equidistant points 
representing design objectives to be minimised and y-axes at those points represent the values 
of corresponding objective functions.  Moreover, four objective functions for each solution 
are connected by a line of specific style and colour. For clarity and ease of discussion, only 
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few non-dominated solutions yielding value for objective-2 is the number of the cells less 
than150. In such case, individuals (solutions) that fall close to x-axis are better than those 
away from x-axis. Moreover, crossing-lines for two consecutive objectives indicate conflict 
between them whereas non-crossing lines indicate that objectives are not in conflict. It is 
observed that a solution giving minimum value along one objective yields relatively higher 
values along other three objective domains. Similar nature is observed with other solutions. 
Although no solution can minimise all four design objective simultaneously to lowest 
possible values because of inherent conflict, each solution has equal potential as per as trade-
off among different objectives are concerned.  
 
Fig. 4.15 Non-dominated solutions of MOGA optimisation at generation-200 
4.4.1   Results 
In order to evaluate the effectiveness of the proposed multi-drug scheduling scheme, 
an example solution yielding a minimum value alone objective 2 (i. e, the number of cells) is 
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performed. To obtain different performance measures in relation to chemotherapy treatment, 
twelve decision variables, which are the controller parameters 
                                       , and three reference inputs (desired drug 
concentrations), of example solution were fed to the I-PDs controllers and the feedback 
control system along with the patient model is simulated for 84 days. Then the output of the 
I-PD controller,                      , and the desired chemotherapy drug scheduling were 
recorded. Several outputs of the patient model, such as, drug concentration at tumour site, 
toxicity and reduction of cancer cells were also recorded. Figure 4.16(a) shows the 
chemotherapy drug scheduling for drugs (A, B and C). The drug doses increase from zero 
and finally become stable at a certain value. It is noted that the rate of increase is different for 
different three drugs. For drug A, the doses took slightly more than one week to reach 
maximum value of 17.12 and for the remaining periods it became stable at that same value. 
For drug B, the chemotherapy drug scheduling took less than one week to reach the 
maximum and stable level of 15 and the doses of drug C got stable at the highest level which 
is 12.5 within one week. 
 
Fig. 4.16 (a) Chemotherapy drug doses for drugs A, B and C 
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4.4.1.1 Drug concentration 
The second graph of Figure 4.16(b) shows the drug concentration at the tumour site 
due to chemotherapy drug scheduling obtained for all cases earlier in the first graph of Figure 
4.16(a). It is interesting to note that the drug concentrations for all cases increase gradually in 
similar manner as observed with the corresponding drug dose scheduling and desired levels. 
The drug concentrations at tumour site reach a maximum value as set by the desired values. 
More importantly, it is noted that, the maximum drug concentrations are always much lower 
than the allowable maximum value indicated in design objective and constraint for this 
particular parameter. 
 
Fig. 4.16(b) Drug concentration for drugs A, B and C for the whole period of treatment 
4.4.1.2 Toxicity 
The toxicities, for drugs A, B and C, developed due to the chemotherapy drug 
scheduling are shown in Figure 4.16(a). For the three cases, the toxicities gradually increase 
from the first day of treatment and finally settle to a steady value after few days in a similar 
manner as observed in case of drug scheduling and drug concentration. The maximum level 
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of toxicity is observed with the drug scheduling obtained with drug A and the value is 92.3 
whereas the minimum toxicity is caused by drug B is 71.7. Toxicities in all cases remain 
under control and much lower than the maximum limiting value set in design objective and 
constraint of the optimisation process.  
 
Fig. 4.16 (c) Level of toxicity for drugs A, B and C for whole period of treatment 
4.4.1.3 Cells reduction 
Figure 4.16(d) shows the reduction of cancer cells during the whole period of 
treatment. The percentage of reductions obtained using the drug scheduling shown in Figure 
4.16 (a) is nearly 100% corresponds to the solution has been chosen. 
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Fig. 4.16 (d) the cell reductions throughout the treatment period 
4.5 Summary 
This Chapter has presented an investigation into the development of multi-drug 
chemotherapy scheduling model using multi-objective optimisation technique.  A novel close-
loop control method was used to design drug doses by maintaining a suitable level of drug 
concentration at cancer sites.  A multi-objective optimal chemotherapy control model used to 
reduce the number of cancer cells after a number of fixed treatment cycles with minimum side 
effects. In the proposed method, several design objectives, constraints and associated goal 
values were defined prior to the optimisation process and a wide range of solutions have been 
obtained satisfying all design goals and trading-off between two main but conflicting 
objectives of chemotherapy treatment; reducing cancerous cells and reducing toxic side 
effects.  
It is interesting to note that the design approach can offer flexibility in decision making 
by the clinicians to pick suitable solution under different trade-off conditions by considering 
the patient’s condition and tumour staging. Many solutions of the proposed drug scheduling 
0 20 40 60 80
0
1
2
3
4
5
x 10
11
time(days)
n
u
m
b
e
r 
o
f c
e
lls
  CHAPTER 4 
 
115 
 
pattern have reduced the number of tumour cells more than 99% with the tolerable drug 
concentration and lower toxic side effects. The proposed model offered better performance as 
compared with existing models with regard to drug resistance and toxicity level.   
The same control strategy and optimisation technique was used to extend for multidrug 
or combination chemotherapy regimen. The model was exploited to demonstrate the effect of 
different drug combinations, doses, and drug resistance. In conclusion, it may be mentioned 
that multi-objective optimisation can be a very useful computing tool to solve complex drug 
scheduling problems in cancers, and other deadly and infectious diseases.  
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CHAPTER 5 
Comparative Performances of the Proposed Schemes 
5.1 Introduction 
This Chapter presents the comparative performances of the proposed models with 
some reported models for optimal drug scheduling for cancer chemotherapy. A close-loop 
control method was used with different structures of PID controller to control the 
chemotherapy dosages infused to the patient throughout the period of a treatment cycle. As 
mentioned in earlier Chapters, the main target of these studies is to achieve a balance between 
the constraints of cancer cell reduction and the side-effect of the treatment. The comparisons 
of these models’ performance include different category (compartments) of cancer cells or 
base of number of drugs have been applied as followed in previous Chapters.  
There are many multi-objectives techniques used to design chemotherapy drug 
scheduling, however, no optimal solution has been implemented yet, as mentioned in Chapter 
2.  The MOGA optimisation process was used to trade-off between the cell killing and toxic 
side effects during the whole period of treatment and to tune the parameters              of 
the (PID) controller with different reference inputs. The process was used to find 
suitable/acceptable drug concentrations at the tumour site by tuning the parameters of the 
controller. A Phase specific and non-phase specific cancer tumour models were used for the 
present study to show the effects of drug in relation to different cell populations, drug 
concentration and toxic side effects. The comparisons show that the employed multi-
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objective optimisation approach can generate a wide range of solutions that trade-off between 
cell killing and toxic side effects and satisfy the associated goals of chemotherapy treatment. 
Depending on the physiological state of the patient and state of the disease, the oncologist can 
pick the right drug schedule suitable for the patient. As mentioned earlier, the cancer 
chemotherapy treatment models have been classified dependent on the functionality of the 
cancer cells. 
5.2 Non-Phase specific 
This section presents a comparative performance analysis of the optimal chemotherapy 
cancer drug scheduling control model to reduce the number of cancer cells after a number of 
fixed treatment cycles with minimum side effects. Non-phase specific models have been 
designed and implemented. Close-loop control methods, namely IPD and PID, are designed to 
control the drugs doses to be infused to the patient’s body. In the proposed method, several 
design objectives, constraints and associated goal values were defined prior to the optimisation 
process and a wide range of solutions have been obtained satisfying all design goals and 
trading-off between two main conflicting objectives of chemotherapy treatment; reducing 
cancerous cells and reducing toxic side effects.  
As discussed in Chapters three and four, our proposed I-PD and PID control strategies have 
been used to control the drug infusion based on Martin’s model (Martin and Teo, 1994) with 
two different references for desired drug concentration at the tumour site. This section also 
presents a comparative performance analysis of the proposed drug scheduling scheme with 
some reported works, as illustrated in Table 5. 1. Here, I-PD and PID controllers with Rep & 
Cont as the reference input have been considered since they offer the best performance in 
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terms of cell reduction among all strategies of chemotherapy drug scheduling investigated in 
this work. Table 5.1 shows the comparative performance of the proposed model with some 
mostly cited reported works in this field (Martin, 1994, Liang et al., 2008, Tan et al., 2002). 
 It is noted that the example solution IPD-1 of the proposed model has reduced the 
cancerous cells to a minimum value of 15, yielding highest index of 24.923 at the end of 
chemotherapy treatment. Another example solution of the proposed method, PID-1, has also 
reduced the number of cancerous cells to nearly the same value, giving a reduction index of 
24.854. These two solutions have outperformed all the results reported so far in 
chemotherapy drug scheduling using Martin’s model. Moreover, other solutions, such as 
IPD-2 and PID-2 have also recorded high index values; 22.654 and 22.368 as far as reduction 
is concerned. More importantly, it is worth mentioning that the proposed method does not 
generate single solution at the end; rather it gives a wide range of very good solutions trading 
off cell reduction and toxic side effect. 
Table 5.1: The numbers of cells remain with different techniques 
Techniques Index (x1) Number of cells remain 
R. Martin, 1994 16.836 4.878X10
4 
Tan et al., 2002 17.993 1.534X10
4   
Liang et al., 2008 20.158 1.760X10
3 
Proposed technique:  IPD-1 24.923 15
 
                                  PID-1 24.854 16 
                                  IPD-2 22.654 145 
This section has also presented a comparative performance analysis of the proposed best drug 
scheduling pattern for non-phase specific cancer cells with some reported works, as 
illustrated in Table 5.1. In order to demonstrate the merits and capabilities of the proposed 
model, we have considered I-PD ‘Rep & Cont’ pattern scheme as it offers the best 
performance among all the proposed patterns. We have compared our results with Liang et 
  CHAPTER 5 
 
119 
 
al., 2008, who used optimal control techniques to control the drug infusion based on Martin’s 
(1994) model, in order to reduce the number of cancerous cells with minimum toxicity level. 
As discussed earlier, our proposed optimal I-PD control strategy has been used to control the 
drug infusion in Martin’s model with three different patterns of drug scheduling, as Liang et 
al., 2008. In order to demonstrate the merits and capabilities of the proposed model, we have 
compared the performance parameters with the best reported model by Liang’s (2008).  
Figure 5.1 shows a comparison of the toxicity level obtained for the different drug 
scheduling patterns. It is noted that the toxicity level of all patterns is within the tolerable 
limit and the ‘Repeated’ pattern is lowest among all the scheduling patterns. However, the 
toxicity level of our proposed model for the best cell reduction scheduling pattern (in this 
case, ‘Rep & Cont’) is familiar to the reported model (Liang et al., 2008) of the same pattern. 
 
Fig. 5.1. Comparative level of final Toxicity for reported (Liang et al., 2008) and proposed 
model 
Figure 5.2 show the drug concentration obtained for all proposed and reported patterns. It is 
observed that the final drug concentration levels of all patterns are within the tolerable limit. 
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Among these the ‘Long Repeated’ patterns of both the reported and proposed models 
achieved lowest level among all. In contrast, the ‘Repeated’ drug pattern of Liang et al., 
(2008) model offered the highest drug concentration level among all the patterns. On the 
other hand, the drug concentration level of our proposed best model (‘Rep & Cont) is 
marginally higher as compared to Liang et al., 2008. It is noted that the drug concentration in 
the proposed method is still lower than the maximum value as indicated in the condition.  
 
Fig. 5.2 Comparative level of final drug concentration into the body for reported (Liang et al., 
2008) and proposed model 
Figure 5.3 shows the number of remaining cells after the treatment cycle. It is noted that the 
‘Rep & Cont’ of the proposed scheduling pattern offers best performance and ‘Repeated’ 
pattern of the Liang’s (2008) offers the worst performance. It is worth mentioning that the 
proposed drug scheduling model for all three patterns performed better then all three patterns 
of the reported model. The performance (based on the remaining cells) of the best scheduling 
pattern ‘Rep & Cont’ of Liang is worse as compared to the proposed best scheduling pattern. 
Finally, the performance of the proposed model is also compared with other reported models 
for 84 days.  
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As mentioned earlier, Table 5.1 shows the comparative performance of the proposed 
model with three other best reported results (Martin and Teo, 1994, Liang et al., 2008, Tan et 
al., 2002). It is noted that the proposed model offers the best performance of all the reported 
results in terms of cancer cell reduction with highest index point. The model proposed by Tan 
et al., (2002) offers the best result compared with all other models which is the index(x1) 
referred to 17.993 in terms of cancer cell reduction. In contrast, Martin’s (1994) model offers 
the worst performance among all the models, which is the index(x1) 16.836. 
 
Fig. 5.3. Comparative performance for reported  (Liang et al., 2008) and proposed model 
Although all solutions on all Pareto fonts as shown in Figures 4.3 (a and b) satisfy design 
objectives by reducing cancerous cells by more than 99% with acceptable toxicity and drug 
concentration, the I-PD controller with Rep & Cont as the reference provides the best 
performances by minimising two conflicting design objectives simultaneously with 
significantly lower values. In order to choose a particular solution from this Pareto set, the 
solution set can be further divided into some regions., Solutions close to example solution I-
PD-1 (see Figure 4.3(a) in Chapter 4) can be termed as high cells killing but high toxicity, 
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solutions around I-PD-2 as moderate cell killing and toxicity and solutions around I-PD-3 as 
low toxicity but low cell killing. Considering the physiological state of the patient and state of 
the cancer, an oncologist can choose a suitable solution from the objective space suitable for 
the patient. For patients having better physiological conditions and requiring faster response, 
chemotherapy drug scheduling resulting from solutions near I-PD-1 can be chosen. On the 
other hand, chemotherapy doses based on solutions residing close to I-PD-3 may be preferred 
for patients having relatively poor physiological conditions and vulnerable to toxic side 
effects. Patients not belonging to the aforementioned two categories may be recommended 
for chemotherapy doses based on example solution I-PD-2 or solutions residing close to it.  
5.3 Phase specific 
5.3.1. Comparative Performance between proposed and reported 
Model 
This section presents a comparative performance analysis of the proposed drug 
scheduling pattern with some reported works using similar cancer tumour models. The 
outputs of the proposed drug scheduling scheme are compared with the results reported by 
(Dua et al. in 2008). The parameters chosen in this work are also used by other authors than 
Dua et al., (2008) as discussed in Chapter 4. Figure 5.4 shows a comparative analysis of the 
reduction in percentage of proliferating and quiescent cells at the end of treatment cycles with 
the proposed model and the reported one in Dua et al. in 2008.   
It is noted in Figure 5.4 that the reduction of proliferating cells in the case of our proposed 
model is 72.5% compared to 70% in Dua et al., (2008) model. It is also noted that the 
reduction of quiescent cells is 61% whereas the reported model yields only 50%.  It is clearly 
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evident that cell reductions for both proliferating and quiescent cells are marginally better in 
the case of the proposed model.  
 
Fig. 5.4 Comparative performance for reported  (Dua et al., 2008) and proposed model 
Dua et al., (2008) designed chemotherapy drug scheduling for cell cycle specific model, as 
used in the present work, and reported reductions for proliferating and quiescent cells at the 
end of treatment, as mentioned earlier. In the present work, Case-1 and Case-2 result (as 
discussed in more details in Chapter 4) in a reduction of 72.5% and 71.2% for proliferating 
cells, which are marginally more than the reported one. More importantly, example solutions; 
Case-1, Case-2 and Case-3 of the proposed work can reduce the quiescent cells up to 60.4%, 
58.9% and 55.1%, respectively, which are significantly higher than the reported result. Figure 
5.5 shows the reductions of proliferating and quiescent cells for Case-1, Case-2, Case-3 and 
Reported work (Dua et al., 2008). It is clearly evident that cell reductions for both 
proliferating (except Case-3) and quiescent cells are better in the case of the proposed model. 
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Fig. 5.5 Reductions of cells for Case-1, Case-2, Case-3 and Reported work (Dua et al., 2008) 
5.3.2 Comparison between MOGA and MOPSO for Phase specific 
Model 
This section presents a close-loop I-PD control method for optimal cancer drug scheduling 
using multi-objective algorithms such as MOGA and MOPSO (Alam, et al., 2010). The two 
main objectives of chemotherapy treatment, reducing cancerous cells and reducing toxic side 
effects, are always found in conflict. Both algorithms MOGA and MOPSO optimisations 
processes are used to design the drug scheduling that trade-off between these two. The 
proposed I-PD controller is designed to control the drug to be infused to the patient’s body for 
a cell cycle specific treatment.  
MOGA and MOPSO are used to tune the parameters for optimal control solution. In the 
proposed method, several design objectives, constraints and associated goal values are defined 
prior to the optimisation process and a wide range of non-dominated solutions have been 
obtained satisfying all design goals, known as Pareto-optimal set, which trade-off among 
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competing objectives. It is interesting to note that the design approach can offer flexibility in 
decision making and a suitable solution can be picked under different trade-off interventions 
for cancer treatment. It is noted that the drug scheduling pattern of the MOGA algorithm 
offers better performance as compared to the MOPSO algorithm.  
Both MOGA and MOPSO optimisation processes were run for 100 generations in order to 
minimise both objectives simultaneously. Solutions not satisfying the aforementioned design 
constraints were penalised with very large numbers, called penalty function. This penalty 
function will reduce the probability of solutions yielding unacceptable values along any 
design objectives that dominate the optimisation process, and on the contrary, favour 
acceptable solutions to be selected for reproduction that in turn may generate better solutions 
in subsequent generations. 
In MOGA and MOPSO optimisation processes, non-dominated solutions called 
Pareto optimal set and corresponding decision variables were updated and preserved at the 
end of each generation. At generation 1, each solution of the initial population was evaluated 
in the problem domain and depending on the values of two objective functions, non-
dominated solutions and corresponding preserved decision variables. A wide range of non-
dominated solution satisfying all design constraints, objectives and associated goal values 
were obtained at the end of maximum generation (=100). For decision making, (i.e., which 
solution to select or use from this wide range of acceptable solutions), the Pareto optimal set 
was redrawn, in a space of two objectives, namely number of proliferating cells and average 
toxicity, which were conflicting each other.  
The objective space was divided into three regions, as shown in Figure 4.9 in Chapter 
4, depending on the values of two objectives for each algorithm; number of proliferating cells 
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and average toxicity. The three solutions selected for MOGA and MOPSO are termed as, 
solution-1 (Sol-1, Case-1): high cells killing but high toxicity, solution-2 (Sol-2, Case-2): 
moderate cell killing and toxicity, and solution-3 (Sol-3, Case-3): low toxicity but low cell 
killing. The locations of solutions in the objectives space clearly indicate performances in 
terms of average toxicity and reduction of proliferating cells at the end of treatment. It is 
evident that solution-1, corresponds to higher cell (proliferating) killing at the cost of higher 
toxicity. The solutions-2 results for both cases show that the rates of the cell killing are 
reasonable with tolerable toxic side effects. It is noted that solution-3 causes minimum toxic 
side effects but the cell reduction is also lowest for these. 
 
Fig. 5.6 Pareto optimal set of MOGA and MOPSO optimisation at generation 100 
In order to evaluate the effectiveness of MOGA and MOPSO in chemotherapy drug 
scheduling, several representative solutions were further assessed. To validate the solution 
set, three solutions were selected on the Pareto front for each algorithm, one from each 
region. The solutions are selected in such a way that two falls on either extreme points of the 
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two objectives, and the other is approximately in the middle of the objective domain. Three 
selected solutions for MOGA, as shown in Figure 5.6, are denoted as case-1, case-2 and case-
3. In the same manner MOPSO also has selected three solutions, Sol-1, Sol-2 and Sol-3 for 
further discussions. To make the chemotherapy drugs effective, the drug concentration at the 
tumour site should be maintained at a desired level for the whole period of treatment and this 
scheme was implemented by using a fixed level of signal, called step input.       
Table 5. 2: Performance measures of drug scheduling techniques 
Example 
solutions 
For the whole period of treatment At the end of 84 days treatment 
Drug doses Drug 
concentration 
Toxicity Reduction of 
Proliferating 
Cells 
Reduction of 
Quiescent 
cells 
No. of 
Normal cells Max Avg Max Avg Max Avg 
Case-1 4.5 3.4 12 9.2 34.5 27.7 72.2% 60.4% 1.0002x10
8
 
Case-2 4.5 3 12 8.3 33.4 23.4 71.2% 58.9% 1.0024x10
8
 
Case-3 4.5 2.8 11.7 7.5 31.9 21.2 68.1% 55.1% 1.2815x10
8
 
Sol-1 4.4 3.9 12 10.6 34.4 30.2 72% 60% 1.03x10
8 
Sol-2 4.4 3.5 12 9.5 32.9 26.9 71% 59% 1.05x10
8 
Sol-3 4.4 3.4 12 9.1 32.8 25.3 68% 55% 1.17x10
8 
In this work, the reference to the controller is selected by trial and error so that the maximum 
toxicity always remains below the maximum allowable value as indicated in design objective 
in Table 5.2, where the minimum value considered as zero. The fixed reference value is set at 
12 in this work.  
To obtain different performance measures in relation to chemotherapy treatment, decision 
variables,   ,    and    corresponding to solutions; case-1, case-2, case-3, Sol-1, Sol-2 and 
Sol-3, were fed to the I-PD controller and the whole system along with the patient model was 
simulated for 84 days. Then the output of the I-PD controller,     , which is the 
chemotherapy drug scheduling was recorded in each case.  Moreover, outputs of the patient 
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model, such as, drug concentration at tumour site, toxicity, reduction of proliferating and 
quiescent cells and changes in normal cells were also recorded due to the infusion of the 
chemotherapy doses. Figure 5.7 show the chemotherapy drug scheduling for Case-1, Case-2, 
Case-3, Sol-1, Sol-2 and Sol-3.  
 
Fig. 5.7 Chemotherapy drug doses for solutions Case-1, Case-2 and Case-3, Sol-1, Sol-2 and 
Sol-3 
Moreover, several performance measures of chemotherapy treatment, such as maximum and 
average levels of drug doses, toxicity and drug concentrations for all six solutions were 
recorded as shown in Table 5.2. Furthermore, percentage of the reductions in proliferating 
and quiescent cells at the end of chemotherapy treatment are also determined and shown in 
Table 5.2. The number of normal cells remaining at the end of treatment gives an indication 
of the physiological state of the patient. So this number was also calculated and displayed in 
the same Table. 
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5.3.2.1 Drug Concentrations 
Figure 5.8 shows the drug concentration against the reference input for both algorithms 
Case-1, Case-2, Case-3, Sol-1, Sol-2 and Sol-3 at the tumour site due to chemotherapy drug 
scheduling. It is interesting to note that the drug concentrations for all cases (selected 
solutions), increase gradually in a similar manner as observed in the case of corresponding 
drug scheduling and follow the reference levels. The drug concentrations at the tumour site for 
the MOGA reach a maximum value as set by the corresponding reference values. It is also 
noted that, like average drug doses, the average drug concentrations also vary from case to 
case; Case-1 having maximum average value of 9.2 followed by Case-2 and Case-3, as listed 
in Table 5.2. While in the MOPSO, the average drug concentrations are different from case to 
case; Sol-1-1 having maximum average value of 10.6 followed by Sol-2 and Sol-3, which is 
slightly high compared to MOGA as listed in Table 5. 2. More importantly, the average and 
maximum drug concentrations are always much lower than the allowable maximum value 
indicated in design objective and constraint for this particular parameter.  
It is important to mention that phase specific chemotherapy drugs, such as Vinca alkaloids, 
Hydroxyurea, Cytosine arabinoside, Methotrexate, 6-Mercaptopurin, 6-Thioguanine, 
Procarbazin, VM-26 and VP16-213 Liang et al., 2008, are, in general, toxic agents and lower 
doses of these drugs may reduce the toxic side effects during the treatment cycle and thereby 
improve the quality of life of the patient (Martin and Teo, 1994). 
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Fig. 5.8 Drug concentration for solutions Case-1, Case-2 and Case-3, Sol-1, Sol-2 and Sol-3 
5.3.2.2 Toxicity 
The toxicities for both algorithms MOGA and MOPSO, for Case-1, Case-2, Case-3, 
Sol-1, Sol-2 and Sol-3, developed due to the corresponding chemotherapy drug scheduling 
are shown in Figure 5.9.  For all cases, the toxicities gradually increase from the first day of 
treatment and finally settle to a steady value after a few weeks, in a similar manner as 
observed in the case of drug scheduling and drug concentration. The maximum level of 
toxicity for MOGA is observed with the drug scheduling obtained with Case-1 and the value 
is 34.5, whereas the minimum toxicity is caused by Case-3. The average toxicities for Case-1, 
Case-2 and Case-3 are 27.7, 23.4 and 21.2, respectively. The maximum level of toxicity for 
MOPSO is observed with the drug scheduling obtained with Sol-1 and the value is 34.4, 
whereas the minimum toxicity is caused by Sol-3. The average toxicities for Sol-1, Sol-2 and 
Sol-3 are 30.2, 26.9 and 25.3, respectively; showing that the average toxicities for MOPSO 
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for are higher than MOGA.  It is important to note that toxicities in all cases remain under 
control and much lower than the maximum limiting value set in design objective and 
constraint of the optimisation process. 
 
Fig. 5.9 Toxicity for all solutions Case-1, Case-2 and Case-3, Sol-1, Sol-2 and Sol-3 
5.3.2.3 Reduction of cells 
One of the aims of chemotherapy treatment is to reduce the proliferation and 
quiescent cells without affecting normal cells much during the treatment. Before the 
treatment starts, the numbers of all cells are listed in Table 5.1, and the number of 
proliferation cells is set at 2x10
11
, as used by many researchers in cell cycle specific cancer 
treatment (Dua et al., 2008). Figure 5.10 shows the reduction of proliferating cells during the 
whole period of treatment. For the MOGA Case-1, Case-2 and Case-3, the percentage of 
reductions obtained using the drug scheduling shown in Figure 5.7 are 72.5%, 71.2% and 
68.1%, respectively. For the MOPSO Sol-1, Sol-2 and Sol-3, the percentage of reductions 
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obtained using the drug scheduling shown in Figure 5. 6 are 72%, 71% and 68%, 
respectively. 
 
Fig. 5.10, Proliferating cells reduction for all solutions Case-1, Case-2 and Case-3, Sol-1, 
Sol-2 and Sol-3 
 It is noted that the MOGA performance of the cell reduction is better when compared to the 
MOPSO. During the treatment period, the number gradually decreases depending on 
chemotherapy drug doses and this is observed for all solutions in Figure 5.9. A similar trend 
is observed in the case of quiescent cells and it is shown in Figure 5.11. It is important to note 
that the reduction for all selected solutions are: Case-1, Case-2, Case-3, Sol-1, Sol-2 and Sol-
3 are 61%, 58.9%, 55.1%, 60%, 59% and 55%, respectively. Figure 5.12 shows the changes 
of normal cells during the whole period of treatment for all solutions. It is mentioned that in 
all solutions, the number of normal cells is higher than the threshold value, as indicated in 
Table 5.2. Moreover, these higher values of remaining normal cells are attributed to lower 
toxic side effects and better physiological conditions of patients. 
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Fig. 5.11 Quiescent cells reduction for all solutions Case-1, Case-2 and Case-3, Sol-1, Sol-2 
and Sol-3 
 
Fig. 5.12 Normal cells reduction for all solutions Case-1, Case-2 and Case-3, Sol-1, Sol-2 and 
Sol-3 
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5.4 Four compartments cancer cells model 
This section presents an investigation into the comparison of a feedback I-PD controller 
for chemotherapy drug scheduling. To the best of our knowledge this is the I-PD based 
chemotherapy control model used to investigate the cell cycle specific treatment.  MOGA has 
also been used to optimise the parameters of the controller. The main objective of the 
proposed control was to enhance the performance of the cancer drug treatment with minimum 
toxic side effects and drug resistance. Model based on the cells function has been used to 
analyse the effects of the drug scheduling designed by the controller. It is noted that the 
obtained drug schedule is continuous in nature having lower and nearly stable values 
throughout the whole period of treatment. The proposed drug scheduling pattern has reduced 
the number of tumour cells significantly with the tolerable drug concentration and toxicity 
level.  
In order to evaluate the effectiveness of the proposed control strategy and MOGA 
optimisation process with cancer cells compartments, an example solution yielding minimum 
value was analysed in detail in Chapter 3. To obtain different performance measures in 
relation to chemotherapy treatment, eight decision variables; 6 controller parameters (    ,     
,    , ,    ,     and    ) and 2 reference inputs (𝑋        𝑋   ) as shown in Figure 4. 11 in 
Chapter 4 were fed to the feedback control system and the whole system along with the patient 
model is simulated for 84 days. Then the outputs of two I-PD controllers,        and       
which are scheduling for drugs A and B were recorded. Several outputs of the patient model, 
such as, drug concentration at tumour site, toxicity and reduction of cancer cells were recorded 
due to the infusion of the designed chemotherapy doses.  
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This compares the effectiveness of the cancer chemotherapy treatments based on drug 
scheduling between a single drug and combination of cancer drugs. Maximum drug doses 
found during the whole period of treatment vary in the range of 10-19, while the average 
remained within 8-13, as shown in Chapter 4, the chemotherapy drug scheduling for single 
drug. It is noted that, the use of Rep & Cont with single drug as the reference input, the drug 
doses sharply rise to a maximum value of 18.5 in the first two days of treatment and then 
slightly reduce on days 3 and 4 followed by a sharp decrease on days 5 and 6. The drug doses 
then rise sharply to a level of nearly 14.5 and remained almost stable till the end of the 
treatment. 
In both drugs, the drug doses increase from zero and finally become stable at certain 
values of 12.91 and 13.12. It is noted that the level of increase is different for two drugs. It is 
worth mentioning that the dosage of the multi-drug is lower compared to the single drug. 
Moreover the effectiveness of the multi-drug by reducing the resistance of the chemotherapy 
cancer treatment increases the performance of the treatment. For drug A, the doses reach 
maximum value of 13.12 within the first week of treatment and for the remaining periods it 
becomes stable at that same value. For drug B, the drug dosage took slightly more than one 
week to reach the maximum and stabilised for the rest of the period at 12.91. 
5.4.1 Drug concentration 
Figure 5.13 shows that the drug concentration of the single chemotherapy cancer drug 
treatment increases and decreases with time in a similar manner as that observed in case of 
drug scheduling. Figure 4.(b) in Chapter 4  shows the drug concentration for  the single drug, 
where the reference input is Rep & Con pattern and it also follows the corresponding drug 
scheduling; as observed the average values are below 35 and the maximum values 50.  
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It is interesting to note that the drug concentrations, for both drugs, increase gradually in 
similar manner as  observed in the case of corresponding drug scheduling and follow 
corresponding references levels/desired levels. The drug concentrations at tumour site reach to 
a maximum value as set by the corresponding references/desired values. More importantly, it 
is noted that the maximum drug concentrations are always much lower than the allowable 
maximum value indicated in the design objective and constraint for this particular parameter.  
 
Fig. 5.13 Comparative level of final drug concentration for the single and multi-drugs 
5.4.2 Toxicity 
The maximum level of the toxicity of the single drug is determined during the whole 
period of treatment, as shown in Figure 5.14. The toxicity sharply rises in the first two days 
because of high drug doses infused to the patient, as shown in Figure 4.13(c) Chapter 4. The 
toxicity then reduces and finally gets stable for the whole period at an approximate level of 
98.7. The toxicities is close to the edge of the critical point, while on the other hand it 
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remains under the maximum limiting value set in design objective and constraint of the 
optimisation process.  
The toxicities, for drug A and drug B, developed due to the corresponding chemotherapy 
drug scheduling are shown in Figure 4.13(b) Chapter 4.  For both drugs, the toxicities 
gradually increase from the first day of treatment and finally settle to a steady value after a few 
days in a similar manner as observed in case of drug scheduling and drug concentration. The 
maximum level of toxicity is observed with the drug scheduling obtained with drug A, and the 
value is 97.5 whereas the toxicity caused by drug B is at the lower level of toxicity in 
comparison to drug A. The level of toxicities for drug A and drug B are 81.7 and 77.5 
respectively. It is noted that levels of toxicity for multi-drug chemotherapy treatment is low 
compared to the single drug. It is important to note that toxicities in all cases remain under 
control and much lower than the maximum limiting value set in the design objective and 
constraint of the optimisation process. 
 
Fig. 5.14 Comparative level of final toxicity for the single and multi-drugs 
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5.4.3 Cells reductions 
The main aim of chemotherapy combination regime treatment is to eradicate/minimise the 
cancer drug resistance to the minimum level after a number of fixed treatment cycles. Before 
the treatment starts for the single drug, the number of proliferation cells is set at 1x10
9
, as used 
by many researchers (Martin and Teo, 1994, Tes, et al, 2007) and reduction of cancerous cells 
for all solutions up to 99%. For the multi-drug the treatment starts, the number of cancer cells 
was assumed 4.60517×10
11
, as used by many researchers in cell cycle specific cancer 
treatment (Dua et al., 2008) whereas the percentage of the reduction approximates nearly to 
100%. Figure 5.15 shows the differences of the reduction between single and multi-drugs of 
cancer cells during the whole period of treatment. It is clear that the multi-drugs gives better 
performance than the single drug regarding the cancer cells reduction at the tumour site during 
the whole period of treatment.  
 
Fig. 5.15 Comparative percentage of the cells reduction for the single and multi-drugs 
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5.5  Eight compartments cancer cells model 
This section presents a comparative investigation for the chemotherapy cancer drug 
scheduling between two algorithms, a proposed one multi-objective genetic algorithm 
(MOGA) and a reported algorithm called memetic algorithm (MA). A proposed novel 
method of multi-drug scheduling uses (MOGA) to find optimum dosages by trading-off 
between cell killing and toxic side-effects of chemotherapy treatment. A close-loop control 
method, namely Integral-Proportional-Derivative (IPD) was designed to control dosages of 
drugs to be infused to the patient’s body and MOGA was used to find suitable parameters of 
the controller. A cell compartments model was developed and used to describe the effects of 
the drugs on different type of cells, plasma drug concentration and toxic side-effects. Results 
in Chapter 4 show that specific drug schedule obtained through the proposed method can 
reduce the tumour size nearly 100% with relatively fewer toxic side-effects. 
The reported method was introduced by Liang and co-worker, 2007, called a new 
memetic algorithm (MA) to solve the Multi-drug chemotherapy optimization problem. A 
multi-drug chemotherapy cancer treatment model is implemented to simulate the possible 
response of the tumour cells under drugs administration. Optimization of the multiple 
chemotherapeutic agents’ administration schedules was based on this tumour model. They 
formulate the optimization problem as an optimal control problem (OCP) with a set of 
dynamic equations. The objective was to design efficient schedules which minimise the 
tumour size under a set of constraints.  
The proposed method investigated and analysed GA parameters and values that yielded 
very satisfactory results in similar applications; the details are described in Section 4.4 of 
Chapter 4. In this investigation a model based on the cells’ function has been used to analyse 
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the effects of the drug scheduling designed by the controller. It is noted that the obtained drug 
schedule was continuous in nature and gives lower and stable values throughout the whole 
period of treatment. 
Many solutions of the proposed drug scheduling pattern have reduced the number of 
tumour cells by more than 99% (eliminate the resistance cells) with the tolerable drug 
concentration and lower toxic side-effects. The proposed model offered better performance as 
compared to existing models with regard to drug resistance and toxicity levels. The drug 
effectiveness (cells reduction) (as shown in Figure 4.16(d) in Chapter 4) in the proposed 
model is nearly 100%, while in the existing it is about 99%. The maximum level of toxicity 
produced by drug A is 92.3 in the proposed model and 100 for all drugs in the existing one 
(Liang et al., 2007).  
Figure 4.16(a) in Chapter 4 shows the chemotherapy drug scheduling for drug A, B and 
C. The drug doses increase from zero and finally become stable at a certain value. It is noted 
that the rate of increase is different for the three different drugs. For drug A, the doses take 
slightly more than one week to reach their maximum value of 17.12 and for the remaining 
periods it becomes stable at that same value. Drug B takes less than one week to reach the 
maximum and stable level of 15 and the doses of drug C get stable at the highest level, which 
are 12.5 within one week. 
5.5.1 Drug Concentration 
Figure 5.16 shows a comparison of the drug concentration between proposed and 
reported methods. The drug concentration at the tumour site due to chemotherapy drug 
scheduling obtained for all cases is shown earlier in Figure 4.16(b) in Chapter 4. It is 
interesting to note that the drug concentrations for all cases increase gradually in a similar 
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manner as observed in the case of corresponding drug dose scheduling. The drug 
concentrations at tumour site reach to maximum values, which are 29, 36 and 39 for drugs A, 
B and C respectively. More importantly, it is noted that the maximum drug concentrations are 
always much lower than the allowable maximum value indicated in the design objective and 
constraint for this particular parameter. In contrast, the MA (Tes et al, 2008), offered highest 
drug concentration level compare to the proposed model, whereas the levels of concentration 
for drugs A, B and C of the reported model are 40, 50 and 50 respectively. On the other hand, 
the drug concentration level of our proposed model is much lower as compared to Tes et al., 
(2008) as Figure 5.16 illustrated. It is noted that the drug concentration in the reported 
method is still lower than the maximum value of the drug concentration limit.  
 
Fig. 5.16 Comparative level of final drug concentration for the reported and proposed model 
5.5.2 Toxicity 
This section presented a comparison of the toxicity for chemotherapy drug scheduling 
of the two algorithms mentioned earlier (MOGA and MA). The main objective of the 
proposed algorithm is to find solutions which enhance the performance of the cancer drug 
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treatment with minimum toxic side effects. A model based on the multi-drug has been used to 
analyse the effects of the drug scheduling designed by the controllers. It is noted that the 
obtained drug schedule is continuous in nature, having lower and nearly stable values 
throughout the whole period of treatment. The toxicities, 92.3, 90 and 71.1 for drugs A, B and 
C respectively, developed due to the corresponding chemotherapy drug scheduling, are 
shown in Figure 4.16(c) of Chapter 4.  
 
Fig. 5.17 Comparative level of final toxicity for the reported and proposed model 
For three cases, the toxicities gradually increase from the first day of treatment and finally 
settle to a steady value after a few days in a similar manner as observed in the case of drug 
scheduling and drug concentration. The maximum level of toxicity was observed with the 
drug scheduling obtained with drug A and the value is 92.3, whereas the minimum toxicity, 
caused by drug B, is 71.7. Toxicities in all cases remain under control and much lower than 
the maximum limiting value set in the design objective and constraint of the optimisation 
process.  
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Figure 5.17 shows the level of the toxicity for both algorithms, whereas the levels of toxicity 
produced by the reported model Memetic Algorithm (MA) (Tes et al., 2008) are higher 
compared to the proposed algorithm. In all cases of the MA the toxicity levels reach 100, the 
maximum tolerable level which should not be exceeded.   
5.5.3 Cell reduction 
The main aim of chemotherapy treatment was to reduce the cancer cells without 
affecting normal cells in the tissue during the treatment. Figure 5.18 shows the percentage of 
reduction of cancer cells during the whole period of treatment for the two algorithms, 
proposed algorithm MOGA and the reported MA one. Before the treatment starts, the number 
of cancer cells is 4.60517X10
11
, as used by many researchers in cell cycle specific cancer 
treatment (Tes et al., 2008). The percentage of the cancer cells reduction for the proposed 
algorithm obtained using the drug scheduling is nearly 100%, which corresponds to the 
solution chosen. Moreover, this higher percentage of the cancer cells reduction is achieved 
with significantly lower toxic side effects and better physiological conditions of patients.  
 
Fig. 5.18: Comparative percentage of the cells reduction for the reported and proposed model. 
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The rate of the cells’ reduction of the memetic algorithm (MA) is lower than the proposed 
algorithm, which is about 99% with higher levels of toxicity as shown in the section above. It 
is important to note that the proposed algorithm MOGA gives better performance as 
compared to the MA Algorithm. In both cases the rate of reduction is steady and reduces to a 
significantly lower value throughout the period of the treatment. 
5.6 Summary 
This Chapter has presented a comparative study of all the different techniques that have been 
used in the earlier Chapters and the outcome for optimal cancer drug scheduling using multi-
objective algorithms. Two main objectives of chemotherapy treatment, reducing cancerous 
cells and reducing toxic side effects are always found to be in conflict. In all techniques, 
optimisations process was used to design the drug scheduling that would trade-off between 
these conflicts. The proposed method was designed to control the drug to be infused to the 
patient’s body for a cell cycle specific treatment.  
A novel close-loop control method was used to design drug doses by maintaining a suitable 
level of drug concentration at tumour sites.  Most used feedback control system; 
Proportional-Integral-Derivative (PID) (Astrom et al., 1993) and a variant of it (different 
structures of PID) were designed to control the drugs to be infused into the patient’s body. A 
multi-objective optimal chemotherapy control model was used to reduce the number of 
cancer cells after a number of fixed treatment cycles with minimum side effects. MOGA and 
MOPSO were used to tune the parameters for optimal control solution. In the proposed 
method, several design objectives, constraints and associated goal values are defined prior to 
the optimisation process. The reported techniques are based on the optimisation process as 
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well, with different controllers to control the drug doses during the treatment cycle. These 
techniques were introduced by many researchers, as mentioned above. 
A comparative study has been presented, based on the reduction of the cancer cells and the 
effectiveness of the treatment. Phase specific and non-phase specific cancer tumour models 
were used for this work to show the effects of drugs on different cell populations, drug 
concentration and toxic side effects. Comparisons show that the employed multi-objective 
optimisation approach can generate a wide range of solutions that trade-off between cell 
killing and toxic side effects and satisfy associated goals of chemotherapy treatment. As 
mentioned earlier, the cancer chemotherapy treatment models have been classified depending 
on the functional state of the cancer cells. 
This Chapter has also presented an investigation into the development of multi-drug 
chemotherapy scheduling model using multi-objective optimisation techniques. An optimal 
control method was used to design drug doses by maintaining a suitable level of drug 
concentration at tumour sites. There were four design objectives: reducing cancer cells, 
reducing toxic side effects for two and three drugs (Four and eight compartments) and 
maintaining the concentration of all drugs at tolerable level. A model based on the cells’ 
function has been used to analyse the effects of the drug scheduling designed by the 
controller. It is noted that the obtained drug schedule is continuous in nature and gives lower 
and stable values throughout the whole period of treatment. Many solutions of the proposed 
drug scheduling pattern have reduced the number of tumour cells by nearly 100% 
(eliminating the resistance cells) with tolerable drug concentration and lower toxic side 
effects. 
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 It is interesting to note that the design approach can offer flexibility in decision making and a 
suitable solution can be picked up under different trade-off interventions for cancer treatment. 
It is noted that the drug scheduling pattern of the MOGA algorithm offers better performance 
as compared to the other algorithms.  
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CHAPTER 6 
Conclusion and Future Work 
6.1 Conclusion 
This thesis has presented an investigation into the development of models for drug 
scheduling and optimisation for chemotherapy cancer treatment. The proposed models, based 
on the cells’ functions, are used to predict and control the tumour growth and explore the 
other effects of treatment. In order to achieve multi-objective optimal control model, close-
loop control methods using the proportional, integral and derivative (PID) are used. The 
Multi-objective Genetic Algorithm (MOGA) method was used to optimise the controller 
parameters, in order to maximise cell killing and minimise the toxic side effects to increase 
the survival time of the patient. The proposed method, several design objectives, constraints 
and associated goal values are defined prior to the optimisation process and a wide range of 
solutions have been obtained, satisfying all design goals and trading-off between two main 
conflicting objectives of chemotherapy treatment, reducing cancerous cells and reducing 
toxic side effects.  
The results of the different optimal scheduling patterns of the proposed models are presented 
and discussed through a set of experiments. The observations are compared with the existing 
models in order to demonstrate the merits and capabilities of the proposed multi-objective 
optimisation models, which reduce the cancer cells by nearly 100% with tolerable levels of 
drug concentration and toxicity. It is noted that the proposed models offer best performance 
as compared to any models reported earlier. 
  CHAPTER 6 
 
148 
 
6.2 List of Contributions 
The main contributions of this research are as follows: 
 Design and Development of a non-phase specific optimal PID and IPD control model 
for chemotherapy drug scheduling.  
 MOGA based control model for phase specific cancer treatments using a single 
chemotherapy.  
 MOGA based control models for cancer treatment using multiple chemotherapy 
drugs.    
6.3 Future Work 
Future research should focus on designing and implementing cancer treatment models 
with real clinical data and considering the biochemical behaviours of the cancer patients. The 
models should also be extended by incorporating the effect of different treatment 
combinations of doses, and different patterns of chemotherapy drug scheduling to generate 
applicable and reliable cancer treatment. 
 The recommendation for the researchers in the next stage could focus specifically on 
the treatment combination and multi-drug scheduling using other strategies in order 
to get better performance. This type of research would increase the effectiveness of 
the treatment as compared to a single drug. 
 Research should be carried out further by focusing on drug resistance as this is a one 
of the important factors for unsuccessful cancer treatment. The investigation can 
consider the cell proliferating cycle which divides the cell cycle in compartments 
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based on the stages of the cell cycling and treatment can be done for each cycle stage 
by different drugs. 
 Finally, the different multi-objective optimisation technique with well as feedback 
control strategy could be used and extended further for any higher combination 
regimen to achieve better performance. Moreover, many design objectives and 
constraints can also be handled to design drug doses for more compartment models. 
The variety of multi-objective algorithms can be a very useful computing tool to solve 
complex chemotherapy cancer drug scheduling problems and other deadly and 
infectious diseases.  
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